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Abstract 
 
Malaria elimination, as outlined by the World Health Organization, is an enticing and 
challenging goal for many malaria endemic regions worldwide. By definition, malaria 
elimination is fundamentally different from malaria control, as the focus shifts from detection 
of parasites in symptomatic patients to detection and clearance of all infections. This includes 
active case detection of asymptomatic persons with sub-microscopic parasitemias who have 
been shown to be able to maintain the cycle of malaria transmission.  
However, the diagnostic tools available for detection of sub-patent, low level parasitemia are 
limited. While expert microscopy has been shown to have a sensitivity of 100% at 50 
parasites/ µL, the sensitivity decreases significantly under field laboratory conditions limiting 
the ability to detect low level parasitemia of all Plasmodium species. Rapid diagnostic tests 
are simple to perform and inform the management of patent clinical cases of malaria. 
However, they are insufficiently sensitive at parasitemias less than 200 parasites/ µL and 
particularly so for non-falciparum Plasmodium species, limiting their role in detecting low level 
parasitemia. PCR is the gold standard, and most sensitive, diagnostic modality, with the 
ability to detect less than 1 parasite/ µL and is readily available in reference laboratories. 
However, the technical requirements and expertise required for performing PCR limits is 
ability to be performed in resource limited settings. Therefore there is a critical need to 
improve the diagnostic repertoire available for detection of low level parasitemia in resource 
limited, malaria elimination settings. 
Loop mediated isothermal amplification (LAMP) is a molecular diagnostic modality that has 
the potential to meet this need. Firstly, although inherently non-quantitative, LAMP is an 
isothermal process relying on the Bacillus stearothermophilus (Bst) polymerase enzyme and 
does not require cyclical temperature changes inherent to PCR. This reduces the logistic 
impediments to field adaptation of a LAMP assay. Secondly, a positive  LAMP reaction results 
in the formation of a magnesium pyrophosphate precipitate which is detectable visually, by 
turbidimetry or using metal ion detectors such as calcein, hydroxynaphthol blue and pico-
green. LAMP end products have also been visualised using melting curve analysis, a 
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bioluminescent output in real time (BART), a lateral flow dipstick or a portable fluorescence 
detection unit (realAmp) thereby simplifying the interpretation of assay results without the 
need for expensive probes and gel electrophoresis. Thirdly, LAMP has been shown to have 
the ability to detect low level parasitemia, to detect all the Plasmodium species and to be able 
to be performed in resource limited settings. 
However, among the limitations to currently available formats of LAMP are that it has limited 
capacity for high throughput processing of samples, for example from cross sectional surveys 
or surveillance studies, as might be required in malaria elimination settings. In addition, 
although there are LAMP primers available for detecting all the Plasmodium species causing 
human infection, their sensitivity for detecting low level parasitemia remains limited, 
particularly for non-falciparum species. 
The hypothesis tested in this thesis is that LAMP can be applied as a high-throughput 
molecular diagnostic tool capable of detecting species-specific low level parasitemia and has 
the capacity to be performed in resource limited settings, towards the goal of malaria 
elimination. The specific aims were 1) to optimise LAMP as a high-throughput assay 
(HtLAMP), 2) to compare HtLAMP to microscopy, rapid diagnostic tests (RDTs) and PCR for 
diagnosing mixed malaria species infections, 3) to develop sensitive LAMP primers for the 
specific detection of non-falciparum Plasmodium species and 4) to validate the HtLAMP 
assay for its ability to be performed in resource limited settings 
This thesis describes the successful optimisation of LAMP into a high-throughput, simple, 
platform for the molecular diagnosis of human Plasmodium parasites and its validation in a 
resource-limited laboratory. It also outlines the process by which novel, highly sensitive LAMP 
primers were developed for the detection of Plasmodium vivax and Plasmodium knowlesi 
species. To my knowledge, these are the most sensitive LAMP primers described in the 
literature to date. 
Taken together, this high-throughput LAMP platform for the identification of non-falciparum 
Plasmodium species has the potential to make a significant contribution to the molecular 
diagnostic tools available for detecting Plasmodium parasites for the purpose of malaria 
elimination. 
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Chapter 1 
Introduction: Malaria and the challenges associated with Malaria 
elimination 
 
Malaria lifecycle 
Malaria is caused by transmission of the protozoan parasite Plasmodium by Anopheles 
mosquitoes. There are 6 species of Plasmodium that are responsible for human disease- P. 
falciparum, P. vivax, P. malariae, P. ovale, which is recognised as 2 subspecies of P. ovale 
wallikeri and P. ovale curtisi [1] and the zoonotic simian parasite P. knowlesi. The malaria life 
cycle occurs in two stages- an asexual reproductive cycle within the human host and a sexual 
cycle within the mosquito vector host (Figure 1.1) [2]. The infected bite of a female mosquito 
of the genus Anopheles, injects sporozoites into the human circulation which migrate to the 
liver to establish an asymptomatic infection within the hepatocyte, lasting 1-2 weeks (for P. 
falciparum) [3]. Merozoites produced during this exo-erythocytic schizogony are released into 
the circulation then invade erythrocytes to establish the asexual erythrocytic schizogony of the 
parasite. It is this stage that is responsible for the clinical features associated with malaria 
infection. Within the erythrocyte, merozoites develop into ring forms, then into trophozoites 
and finally into schizonts over 48 hours (P. falciparum, P. vivax, P. ovale) or 72 hours (P. 
malariae), before rupturing the erythrocyte to release 24 to 32 merozoites from each schizont 
capable of infecting more erythrocytes [4]. During this erythrocytic cycle, some parasites 
switch to sexual forms of male and female gametocytes. An Anopheles mosquito ingests the 
gametocytes during a blood meal from an infected human host. The male gametocytes 
releases 8 exflagellated microgametes which fertilise a female macrogamete to form a diploid 
zygote which in turn differentiates into an ookinete that burrows across the wall of the 
mosquito midgut to develop into an oocyst containing many sporozoites [4]. The sporozoites 
are then carried by the insect hemolymph into the mosquito salivary glands in preparation for 
transmission to a human host. This sporogonic cycle within the vector requires a period of 1-2 
weeks. 
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Figure 1:1 Malaria lifecycle (courtesy of CDC, http://www.cdc.gov/malaria/about/biology/) 
 
Malaria incidence 
Malaria continues to be responsible for significant morbidity and mortality worldwide. The 
2014 WHO Malaria report estimated 198 million cases of malaria globally in 2013 which were 
complicated by 584,000 deaths, 78% of which were in children under the age of 5 years in the 
WHO African region [5].  
However, the current incidence of malaria infections represents a significant improvement 
compared to the 227 million cases reported in the year 2000 as a result of large-scale 
investment in malaria control programs, and worldwide initiatives to reduce the number of 
malaria cases (Figure 1.2). Of note, 55 of 106 countries that reported ongoing transmission in 
2000 appear to be on track to meet the Roll Back Malaria and World Health Assembly target 
of reducing malaria cases by 75% from by 2015, with a further 12 countries reporting no 
indigenous cases in 2013 [5]. However, these 55 countries accounted for only 6% of the total 
estimated cases in 2000. Therefore, while worldwide estimated malaria mortality rates fell by 
47% in all age groups between 2000- 2013, it is of significant concern that 90% of malaria 
deaths were concentrated in the WHO Africa region [5]. 
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Figure 1:2 Projected changes in malaria incidence, by country, 2000-2015  
(WHO World Malaria Report 2014 page 33) 
 
Malaria Elimination 
Nevertheless, in the context of significant improvements in malaria control over the last 15 
years, the long term goal for malaria initiatives worldwide has become malaria elimination and 
eventually, malaria eradication. Malaria control is defined as ‘the reduction of malaria disease 
burden to a level at which it is no longer a public health problem’. Malaria elimination is 
defined as ‘the reduction to zero of the incidence of infection caused by human malaria 
parasites in a defined geographical area as a result of deliberate efforts and continued 
measure to prevent re-establishment of transmission’ while malaria eradication is defined as 
‘permanent reduction to zero of the worldwide incidence of infection caused a by a particular 
malaria parasite species where intervention measures are no longer needed’ [6]. Feachem et 
al. also proposed the term ‘malaria eliminating country which is a ‘country in the process of 
moving from controlled low endemic malaria towards elimination’ [7]. 
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As of 2014, 19 countries were in the elimination or pre-elimination phases, with a further 7 
countries in prevention of re-introduction phase [5] (Fig 1.3) 
  
Figure 1:3 Worldwide distribution of malaria and malaria burden stages of each country 
(www.rbm.who.int) 
 
Challenges for malaria elimination 
A framework consisting of three components was developed for approaching malaria 
elimination. Firstly it aimed to reduce the burden of disease in high endemic countries through 
continued implementation of malaria control strategies. This has been reflected in ongoing 
reductions in malaria incidence [5]. Secondly, the strategy focused on ‘shrinking the malaria 
map’ by focusing on achieving elimination in countries on the margin of endemic regions, and 
thirdly on research into key aspects such as drugs, vaccines and diagnostics to facilitate and 
maintain malaria elimination [8].  
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However, there are significant challenges to the goal of malaria elimination including technical 
[9], operational [10] and financial [11] considerations. The malaria eradication research 
agenda (malERA) initiative further detailed the challenges associated with interrupting malaria 
transmission ranging from diagnostics, vaccines, drugs and vector control to operational 
research and surveillance [12]. Furthermore, from an organism point of view, P. falciparum is 
the species associated with the most significant morbidity and the predominant species 
responsible for malaria associated mortality in children under age 5 in the African region. 
Therefore it is the key focus of elimination activities [12]. However, in much of Latin America, 
South-east Asia and the Pacific, P. vivax is the dominant species, often co-existing with P. 
falciparum, and capable of significant morbidity and even mortality. Therefore, it represents 
an important target in malaria eradication efforts. However, P. vivax poses additional 
challenges to eradication due to its capacity for hypnozoite formation in the liver, for which no 
diagnostic techniques currently exist. Furthermore, treatment options are limited to 
primaquine, which poses a significant risk of haemolysis in persons with glucose-6-phosphate 
dehydrogenase (G6PD) deficiency, a condition for which rapid, affordable and reliable point of 
care diagnostic tools are still under development. 
 
The asymptomatic, sub-microscopic reservoir of malaria 
Microscopic examination of thick and thin blood films is the gold standard for the diagnosis of 
malaria, particularly in relation to point of care diagnosis for malaria infection. However, it is 
well established that the quality of microscopy for malaria detection is operator-dependent, 
particularly at low parasitemia. Thus the sensitivity of field microscopy is less than 10% 
compared with expert microscopy at parasitemias of less than 500 parasites/ µL [13]. This 
has been shown to have important implications for the purpose of malaria elimination, where 
P. falciparum parasite prevalence measured by microscopy was only 50.8% of that measured 
by PCR, and this discrepancy is even greater in low transmission settings [14]. For P. vivax, 
microscopy failed to detect 69.5% of PCR detectable infections and moreover, the relative 
proportion of infections that were submicroscopic was higher for P. vivax compared with P. 
falciparum [15]. Several other studies from different geographic regions have also 
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demonstrated the underestimation of parasite prevalence based on microscopy [16-18] as 
well as rapid diagnostic tests (RDTs) [19]. 
The extent of the asymptomatic, submicroscopic reservoir has important implications for 
malaria elimination efforts, particularly from the point of view of maintaining transmission. 
Although the lowest parasitemia that permits ongoing transmission is unclear, residual 
submicroscopic parasitemia after treatment with artemisinin combination therapy (ACT) has 
been shown to be associated with longer gametocyte carriage, risk of relapse of infection, and 
importantly a nearly 2 fold higher relative risk of infecting mosquitoes [20]. Furthermore, 
certain geographic regions or demographic subpopulations, identified by seroprevalence 
studies and known as ‘hot spots’ or ‘hot pops’ have been shown to be able to maintain 
transmission of parasites even in low transmission areas [21, 22].  Therefore identifying and 
targeting interventions towards this asymptomatic population with submicroscopic parasitemia 
will be an essential component of malaria elimination efforts. 
 
Active case detection and management strategies 
However, the best approach for detecting asymptomatic, submicroscopic malaria infections 
remains unclear. Passive case detection, based on identifying symptomatic patients, which 
remains the approach for malaria control programs has been superseded by active case 
detection (ACD) for the purpose of malaria elimination [23]. As defined by the WHO, active 
case detection is ‘the detection by healthcare workers of malaria infection at community and 
household level in population groups that are considered to be at high risk. Active case 
detection can be conducted as fever screening followed by parasitological examination of all 
febrile patients, or by parasitological examination of the target population without prior 
screening [24]. ACD can be implemented as reactive active case detection (RACD) where 
screening is initiated by the detection of an index case of infection or proactive active case 
detection (PACD) which is the screening and treatment of specific communities considered at 
high risk [23]. However, in the absence of a standardised approach, regions pursuing 
elimination have varying methods of implementing ACD [25].  
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Implementation of ACD, particularly as a mass screening and treatment (MSAT) approach, 
also involves choosing the most appropriate diagnostic tool to identify both parasitemic 
individuals as well as an appropriate antimalarial agent. Microscopy and rapid diagnostic tests 
(RDTs) remain the backbone of malaria diagnosis. While PCR and other molecular 
diagnostic, such as loop mediated isothermal amplification (LAMP) and NASBA, are 
available, each have their limitations in terms of applicability for the purpose of malaria 
elimination. However, MSAT of RDT positive individuals has been shown to be ineffective at 
reducing malaria incidence most likely due to the number of diagnoses missed as a result of 
the use of a diagnostic tool with limited sensitivity at low parasitemia [26, 27]. This is in 
keeping with modelling studies that have shown that targeted mass drug administration 
(tMDA) based on, for example, RDT prevalence of 20% would result in treatment of 55% of 
PCR positive infections but 45% of infections would remain untreated [28]. This suggests that 
availability of sensitive molecular diagnostic tools is essential for effective implementation of 
ACD and these are discussed in detail in chapter two in terms of their field applicability and 
potential for high throughput for the purpose of applicability for malaria elimination. 
The alternative to ACD, for the purpose of malaria elimination, is mass drug administration 
(MDA) [29, 30] which alleviates the issue of missed infections.  However, the issues 
associated with MDA are complex- there is a negative historical precedent for MDA in malaria 
eradication efforts and the most appropriate choice of antimalarial agent is uncertain given 
that artemisinin combination therapy (ACT) is an effective schizontocidal drug but does not 
clear gametocytemia while primaquine is gametocidal and effective again P. vivax 
hypnozoites but is associate with hemolysis in persons with glucose-6-phosphate 
dehydrogenase (GDPD) deficiency [23, 31]. Therefore unnecessary exposure of uninfected 
persons to these antimalarial agents as part of MDA campaigns will be associated with side 
effects and parasite selective pressure, neither of which are desirable outcomes particularly 
given increasing evidence of spread of P. falciparum parasite resistance to ACT in Southeast 
Asia [32]. Furthermore, to date the effectiveness of MDA in achieving elimination has not 
been well established. 
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Conclusion 
While there have been significant reductions in malaria incidence as a result of investment in 
malaria control programs worldwide, in order to achieve malaria elimination significant logistic, 
diagnostic, treatment and surveillance challenges are yet to be overcome. 
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Chapter 2  
Diagnostic tools for the purpose of malaria elimination 
 
As outlined in Chapter One, there are many challenges that will need to be overcome in order 
to achieve malaria elimination. One of these is the availability of the appropriate diagnostic 
tools. Microscopy and rapid diagnostic tests (RDTs) have formed the backbone of diagnostic 
techniques for malaria control. However, they are insufficiently sensitive for the detection of 
low level parasitemia, particularly in asymptomatic persons, as is likely to be necessary for 
the purpose of achieving malaria elimination. PCR is the most sensitive diagnostic tool 
currently available for detecting low level parasitemia and is readily available in referral 
laboratories. However, due to technical expertise required and equipment costs associated 
with PCR, it remains unsuitable for application in resource limited settings. Loop mediated 
isothermal amplification (LAMP) has emerged as a potential field applicable molecular 
diagnostic technology that may have the potential for field applicability and be suitable for the 
purpose of malaria elimination 
In this literature review, published in the Malaria Journal, I evaluated the currently available 
novel molecular techniques in terms of their ability to detect low level parasitemia, their 
capacity for high throughput as might be required for performing large scale surveillance 
studies and their ability to be performed in resource limited settings as may be required of a 
diagnostic tool for the purpose of malaria elimination. 
 
Britton S, Cheng Q, McCarthy JS, Novel molecular diagnostic tools for malaria elimination: a 
review of options from the point of view of high-throughput and applicability in resource limited 
settings, Malaria Journal 2016, 15(1):88 
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Abstract 
As malaria transmission continues to decrease, an increasing number of countries will enter 
pre-elimination and elimination. To interrupt transmission, changes in control strategies are 
likely to require more accurate identification of all carriers of Plasmodium parasites, both 
symptomatic and asymptomatic, using diagnostic tools that are highly sensitive, high 
throughput and with fast turnaround times preferably performed in local health service 
settings. Currently available immunochromatographic lateral flow rapid diagnostic tests and 
field microscopy are unlikely to consistently detect infections at parasite densities less than 
100 parasites/ µL making them insufficiently sensitive for detecting all carriers. Molecular 
diagnostic platforms, such as PCR and LAMP, are currently available in reference 
laboratories but at a cost both financially and in turnaround time. This review describes the 
recent progress in developing molecular diagnostic tools in terms of their capacity for high 
throughput and potential for performance in non-reference laboratories for malaria elimination. 
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Introduction 
Malaria continues to be a significant public health issue, with 198 million cases of infection 
occurring in 2013 [1]. However, it is estimated that 55 of the 106 countries that reported 
ongoing transmission in the year 2000 will, by 2015, meet the target of reducing malaria case 
incidence rates by 75%. In this context, in 2007, the WHO endorsed the ambitious goal of 
achieving worldwide malaria elimination and eradication. The definitions and associated 
challenges of elimination have been previously discussed [2, 3]. 
Inherent to a change in focus from control to elimination is the need to interrupt transmission 
which requires identification and treatment of all parasite carriers, both symptomatic and 
asymptomatic. To this end, there is increasing appreciation of the extent of the asymptomatic 
reservoir of malaria parasites, their potential to maintain transmission and the role that 
sensitive diagnostic tests will need to play in providing accurate epidemiological information to 
guide programmatic changes. A review by Okell et al. found that for P. falciparum, microscopy 
underestimated prevalence by 50.8% compared with PCR, and that this gap became even 
more significant in low transmission settings [4]. Similarly, Cheng et al. described 
submicroscopic P. vivax infection being highly prevalent particularly in areas of low 
transmission with on average 69.5% of infections being detected only by PCR [5].  
The diagnostic tools currently available for the identification of Plasmodium spp include light 
microscopy, immunochromatographic lateral flow assays (known as rapid diagnostic tests, 
RDTs), serology, fluorescence microscopy and nucleic acid amplification techniques (NATs), 
such as PCR and isothermal amplification. Light microscopy has poor sensitivity in low 
transmission setting and in asymptomatic patients, resulting in underestimation of disease 
prevalence compared with the gold standard molecular diagnostic tool, PCR [4-6]. Even the 
most sensitive RDTs share similar limitations with microscopy [7], and have been shown to be 
insufficiently sensitive for community screening of asymptomatic carriers of P. falciparum [8, 
9]. Furthermore, mass screening of populations in five malaria ‘hot spots’ in Zanzibar and 
treatment of RDT positive individuals did not reduce malaria incidence[9] likely due to the 
nearly 10 fold higher undetected and untreated infection reservoirs missed by RDTs 
(compared with PCR). Therefore, diagnostic tools with better analytical sensitivity are likely to 
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be required to detect the low level parasitemia associated with asymptomatic carriage of 
Plasmodium spp pertaining to the goal of malaria elimination. 
The Malaria Eradication Consortium has outlined features required of diagnostic tools for the 
purpose of malaria elimination [10]. These were further modified by the WHO in 2014 [11] to 
include a lower limit of 2 parasites/ µL detected in order to be ‘a significant improvement on 
expert microscopy’. However, the minimum number of parasites per microlitre that 
perpetuates transmission in low transmission settings remains uncertain.  
For malaria elimination, the strategies for interrupting the cycle of transmission rely on 
enhanced population surveillance to inform additional intervention.  Surveillance for 
elimination includes reactive and proactive active case detection, mass screening/testing and 
treatment (MSAT/MTAT), focused screening and treatment (FSAT) [12] and mass drug 
administration (MDA) [13, 14]. However, the most effective of these strategies remains to be 
determined. While the success of each of these strategies will depend on a number of 
different factors, the feature common to each of them, except MDA, may be the availability of 
point-of-care, sensitive diagnostic tools that are able to process large numbers of samples 
with a fast turnaround time. 
NATs are currently the most sensitive diagnostic modality available, and many different 
assays have been developed for the identification of Plasmodium parasites. The performance 
of these assays, in terms of their accuracy, has been comprehensively reviewed recently [15]. 
However, while readily available in reference laboratories, NATs such as PCR remains 
inaccessible in resource limited settings due to the expensive infrastructure, reagents and 
technical expertise required. Efforts to improve the field applicability of NATs have resulted in 
the development of assays such as PCR-enzyme linked immunosorbent assays (PCR-ELISA) 
[16], nucleic acid lateral flow immunoassay (NALFIA) [17, 18], nested PCR-high resolution 
melting analysis (nPCR-HRM) [19], PCR-ligase detection reaction assays (PCR-LDR) [20] 
and modifications of PCR-LDR into LDR- fluorescent microsphere assay (LDR-FMA) [21]. 
These assays, which have been recently reviewed [22], have good analytical sensitivity but 
are limited in their field applicability by virtue of their requirement for a PCR amplification step. 
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Isothermal molecular diagnostic modalities, such as loop mediated isothermal amplification 
(LAMP), nucleic acid sequence based amplification (NASBA), thermophilic helicase 
dependent amplification (tHDA) and recombinase polymerase amplification (RPA), which 
have also been detailed elsewhere [23], are of much current interest given their potential to 
combine good analytical sensitivity with technical requirements that may facilitate application 
in resource limited settings.  
Several NATs, including quantitative PCR (qPCR) combined with microfluidics [24], and those 
linked to enzyme-linked immunosorbent assays [25-27] as well as non-nucleic acid 
techniques [28-30] are in development for the purposes of malaria diagnosis but are not 
discussed further here. 
However, for even the most promising molecular technologies to be useful as point of care 
(POC) tests, significant challenges of portability, sample preparation, power supply and high 
throughput [31] have yet to be overcome.    
This review describes the currently available novel molecular diagnostic platforms for the 
detection of low parasitemia from the point of view of their potential for high-throughput and 
applicability in resource limited settings for the purpose of malaria elimination. 
 
Nucleic acid amplification techniques (NATs) 
PCR is a very sensitive molecular diagnostic modality capable of identifying asymptomatic, 
submicroscopic infection. The sensitivity of PCR for identifying low level parasitemia has been 
shown to be improved by performing qPCR using DNA from high blood volumes (upto 1 ml). 
The latter platform, as described by Imwong et al., has a limit of detection (LOD) of 0.022 
parasites/ µL [32]. This has been achieved using a modified Qiagen© extraction protocol with 
extraction of DNA from 1 ml of blood, then concentrated to a volume of 10 µL of DNA with 2 
µL of template per reaction (therefore equivalent to 200 µL of blood) in combination with 
primers to a P. falciparum 18S rRNA gene target [32]. The process is amenable to up-scaling 
through automation to test up to 700 samples per week, confirming its status as a high-
throughput diagnostic modality. While this technique when offered in a reference laboratory 
could make a significant contribution to the detection of low level parasitemia, its significant 
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drawback is the need for venipuncture which is impractical for population surveillance 
purposes. In addition, the equipment, reagents and technical expertise required are likely to 
preclude its use as a field deployable test. Nevertheless, it highlights the significant diagnostic 
advantages associated with sample concentration for identification of low level parasitemia.  
The assay has been shown capable of identifying most infected individuals in malaria 
endemic areas based on the distribution of parasite densities in asymptomatic malaria 
determined by this assay [33]. 
Efforts to simplify PCR for the purpose of field application have seen PCR performed directly 
on blood and combined with NALFIA [18] and multiplex malaria sample ready (MMSR) 
assays [34]. The MMSR assay relies on the lyophilisation of all multiplex qPCR reagents in 
either 8-tube strips or 96 well plates which requires only the addition of sample DNA and 
water for the identification of Plasmodium genus and P. falciparum at an LOD of 0.244 
parasites/  µL from whole blood. The assay can also identify P. vivax. Although MMSR still 
requires a thermocycler, DNA extraction and is expensive (> US$ 10 per reaction), it 
overcomes some significant issues associated with performing PCR in resource limited 
settings, thereby providing proof-of-concept for the potential PCR has to become deployable 
in non-reference laboratory settings. 
To overcome the issue of equipment in field settings, Canier et al. created a mobile molecular 
laboratory [35]. At a cost of US$ 200,000 for the fully equipped truck, this laboratory is able to 
process 240 samples per day, with a turnaround time of 24 hours and a cost of US$ 2.75/ 
sample. The real time assay was performed in a 96-well plate using DNA extracted from filter 
paper using a commercial kit (Instagene Matrix resin, BioRad). Samples were screened for 
Plasmodium spp using a mitochondrial cytochrome-b target [36]and then a species-specific 
nested real time PCR performed to arrive at an LOD of 2 parasites/ µL from a 5 µL dried 
blood spot (DBS) [35]. While this innovative approach provides the opportunity for performing 
field-based PCR with its associated high throughput and fast turnaround time, the cost outlay 
of the mobile laboratory and cost per sample may be prohibitive in many developing countries 
embarking on malaria elimination programs. 
A significant advantage of real-time PCR is the lack of post-PCR handling through the use of 
fluorophores.  To overcome issues of expense, Lucchi et al. [37] developed a novel, low cost 
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technique for labelling real-time PCR primers with  self-quenching ability via photo-induced 
electron transfer (PET). The PET-PCR assay was performed on Qiagen©-extracted DNA 
using a duplex of Plasmodium genus and P. falciparum primers, and was found to have an 
LOD of 3.2 parasites/ µL [37]. Validation of the assay on nearly 3,000 surveillance samples 
from Haiti, took over 5 months to process [38]. Therefore, while PET-PCR would appear to 
offer a sensitive platform for performing real time PCR, it is unclear whether the overall cost of 
the technology coupled with turnaround time would render it amenable for field deployment 
for malaria elimination. 
Portable, self contained molecular technology is the ultimate prize in the development of field 
applicable diagnostic tools. The first of these is based on a plastic hydrogel chip and a 
customised portable real time PCR machine (Gelcycler) [39]. The assay can process 12 
samples at a time, directly from whole blood, with no prior DNA extraction. The assay uses an 
18S rRNA gene target that detects all species of Plasmodium with an LOD of 2 parasites/ µL 
and differentiated between P. falciparum and P. vivax [39]. The assay had a 2 hour 
turnaround time using a 12 volt battery and costs US$ 1 per test and US$ 2,000 for the 
gelcycler [39]. Although able to process only 12 samples at a time, the low cost, self 
contained nature of this chip and ability to test blood directly with a fast turnaround time make 
it an enticing prospect for field applicable diagnostics. The second platform is a multiplex 
microarray assay, targeting 26 tropical pathogen species including P. falciparum and P. vivax, 
with a turnaround time of 4 hours [40]. However, its cost and loss of sensitivity at less than 
100 parasites/ µL for P. falciparum suggest a limited role for the assay for the purpose of 
malaria elimination. 
Another approach to increasing sample throughput is pooling of samples [41]. In this study by 
Hsiang et al., filter paper samples were pooled into groups of 10, 50 and 100 and tested by 
real time PCR and species differentiated using a restriction enzyme analysis. The study found 
that at 10 parasites/ µL, a pool of 10 had a sensitivity of 93% for P. falciparum [41] but 
turnaround time, throughput and cost of this approach are unclear. However, pooling 
strategies are only likely to be cost effective in areas with very low level transmissions, and 
where parasitemic subjects have moderate parasitemias, which may permit pooling of DNA 
samples, thereby limiting its potential role in elimination settings.  
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Finally, RNA assays are generally considered too technically challenging for application in 
resource limited settings. Nevertheless, Cheng et al. have developed a capture and ligation 
probe PCR (CLIP-PCR) where sample lysate are directly incubated with a target plate 
overnight, obviating need for RNA purification and reverse transcription. qPCR can then be 
performed and results analysed by melting curve analysis and cycle threshold values. It is 
high throughput by virtue of its 96-well plate format and sample pooling, and can be 
performed directly from whole blood with an LOD of 0.05 parasites/ µL or from pooled DBS 
with an LOD of 0.3 parasites/ µL [42]. More than 3,000 DBS were processed in the study but 
throughput per day is unclear. Limitations are an overnight incubation step which extends 
turnaround time, ability to identify only Plasmodium genus and requirement for PCR. 
Nevertheless, the potential for high throughput and direct processing from blood opens the 
possibilities for RNA assays to enter the foray of diagnostics for malaria elimination. 
 
Loop mediated isothermal amplification (LAMP) 
Since its first description in 2001 by Mori et al. [43], LAMP has become a forerunner in 
isothermal diagnostic technology for the identification of Plasmodium species [23]. LAMP has 
been used to identify all human Plasmodium species [44] including P. knowlesi [45, 46], and 
LAMP primers have been optimised to improve the sensitivity with which P. falciparum [47, 
48] and P. vivax [49, 50] can be detected. A commercially available Loopamp kit (Eiken 
Chemical co) has been validated for the detection of P. falciparum [51] and enables the 
indirect detection of P. vivax using a combination of pan-genus and P. falciparum specific 
LAMP primers [52].  Given that the commercial LAMP turbidimeter has limited capacity, 
Loopamp kits have been successfully combined with 46-well heat blocks and UV lamps to 
increase throughput [53, 54]. Nevertheless, further optimisation of LAMP platforms will be 
needed in order to viably process large numbers of samples as might be required to broaden 
its applicability for malaria elimination [31, 55].  
Goto et al. [56] described a simple LAMP platform to improve its throughput using a 96-well 
microtitre plate format and a metal ion detector, Hydroxynaphthol blue (HNB), for rapid visual 
interpretation of positive and negative results. This platform has been adapted for the 
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identification of Plasmodium genus and P. falciparum as a high-throughput LAMP (HtLAMP) 
assay that can be combined with a portable photospectrometer for objective confirmation of 
visually detectable HNB colour change results [57]. Its LOD for the identification of 
Plasmodium genus (HtLAMP-Pg) is 2.5 parasites/ µL from whole blood and 25 parasites/ µL 
from DBS.  The cost of HtLAMP-Pg is US$ 1 per sample which includes whole blood DNA 
extraction using a modified chelex-saponin protocol. Although HtLAMP requires DNA 
extraction and is yet to be validated on asymptomatic patient samples to confirm throughput 
capacity, it has been performed in a resource limited setting and offers a cost effective 
molecular diagnostic platform. 
Notwithstanding the issue of high-throughput, one of the exciting aspects of LAMP has been 
its potential for field deployment by virtue of its isothermal nature, and as such efforts have 
been invested in improving its field readiness. Lucchi et al. described the RealAmp platform in 
which LAMP was housed in a portable tube scanner with a built-in fluorescent detection unit 
able to monitor the generation of fluorophores by SYBR green in real time rather than reliance 
on visual colour change [58]. The device is a compact, 8 tube well, closed-system with an 
LOD of 0.4- 40 parasites/ µL for Plasmodium genus detection depending on method of DNA 
extraction. Costs are quoted at US$ 6,344 start-up and US$ 2.66 per sample at minimum.  
RealAmp has also been used to detect P. vivax [49], and has been validated in field testing 
[59].Therefore, while this platform itself appears portable and relatively sensitive, its potential 
role in malaria elimination may be limited by its throughput and cost. 
The concept of lateral flow based immunodiagnostics is familiar to the field of malaria. LAMP 
has been combined with a lateral flow device (LFD) thus adapting a molecular assay into a 
rapid diagnostic device [60]. This LAMP-LFD assay, performed on extracted DNA or directly 
on blood, targets the dihydrofolate reductase thymidylate synthase (dhfr-ts) genes of P. 
falciparum and P. vivax using biotynylated LAMP primers whose products then hybridised 
with FITC labelled single strand DNA. A strepavidin-biotin reaction between hybridised LAMP 
amplicons and gold-labelled anti-FITC antibodies on the LFD strip allow visualisation of the 
result [60]. However, this LAMP-LFD platform has limited sensitivity at low level parasitemia, 
and has not been validated on clinical samples. Importantly, it is a multistep process, 
requiring the addition of the probe at the end of the LAMP reaction, making this open system 
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vulnerable to contamination, particularly where high throughput sample processing is 
necessary. Nevertheless, the potential for simple visualisation of results offered by LFD, 
combined with either LAMP [60], recombinase polymerase amplification (RPA) [61] or PCR 
[18], is promising. 
Field applicability of diagnostics devices centre around simplicity of the assay and ability to be 
performed with minimal instrumentation but generally still depend on a reliable electricity 
supply. Non-instrumented nucleic acid amplification (NINA)[62] has been applied to the 
detection of Plasmodium species as a LAMP-NINA assay [63]. This assay uses an 
exothermic chemical reaction between saline and a magnesium iron alloy to generate a heat 
source for performing LAMP on a maximum of 5 samples within an insulated thermos flask-
like device, and was validated in Ethiopia using Loopamp malaria pan genus/Pf kits (Eiken 
chemical co, Japan) in the NINA heating device [63]. Its limitations are its lack of capacity for 
high throughput, risk of contamination and validation only in samples with relatively high 
parasitemia. However, the self-contained electricity free heating device, lack of post 
processing handling and fast turnaround time make it an attractive prospect as a field 
applicable point of care diagnostic device. 
 
Conclusion 
The extent of the submicroscopic parasite reservoir is becoming more evident with the 
utilisation of sensitive, reference laboratory-based PCR testing. Microscopy and RDTs have 
been shown to underestimate the Plasmodium parasite prevalence in low incidence settings 
when compared with PCR, which has important implications for malaria elimination [9, 64]. 
The availability of sensitive diagnostic tests would also facilitate improved diagnosis of causes 
of febrile illness as malaria incidence declines and allow for more appropriate administration 
of artemisinin combination therapy (ACT) [19]. Although many diagnostic platforms may be 
capable of fulfilling this role, given the sensitivity of NATs, there is an increasing priority for 
the development of molecular diagnostic tools that have the capacity for detection of low level 
parasitemia, that are able to process large numbers of samples and that can be performed in 
regional, non reference laboratory settings in order to support efforts of malaria elimination. 
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The various novel PCR and LAMP platforms currently available (Table 2.1) have 
demonstrated variable analytical sensitivity; many of these have yet to be validated among 
asymptomatic patients for the specific purpose of identifying low level parasitemia and have 
yet to be evaluated in resource limited settings. The main dichotomy between the two types of 
molecular assays remains that PCR-based assays have the sensitivity of parasite detection 
and the infrastructure support to increase throughput of sample processing, but have limited 
capacity to be deployable to more resource-limited laboratory settings. Isothermal assays, 
such as LAMP on the other hand, appear to have adequate analytical sensitivity to detect low 
level parasitemia and strong potential for deployment in non-reference laboratory settings but 
have limited, often implied rather than proven, capacity for high throughput processing of 
samples. Furthermore, many of these platforms are yet to overcome the common hurdle of 
simplifying nucleic acid extraction, an essential requirement for such assay platforms in 
resource limited settings.  Both PCR and LAMP based assays are currently more expensive 
than RDT. 
Nevertheless, engineering challenges may be surmountable and strong foundations have 
been laid for achieving the goal of developing sensitive molecular diagnostic tools with the 
capacity for both field deployment and high throughput sample processing for the purpose of 
detecting low level parasitemias in malaria elimination settings. 
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Table 2:1: Summary of capacity for high-throughput and potential for field applicability of microscopy, RDT and novel nucleic 
acid amplification platforms 
Diagnostic 
modality 
Platform Limit of 
detection 
(parasites/µL
) 
Number of samples 
processed (per assay or 
per day) 
Validated on 
symptomatic or 
microscopy 
positive samples 
Validated on 
asymptomati
c or 
surveillance 
samples 
Assay 
evaluated in 
resource-
limited setting 
Cost
† 
 
Microscopy Light microscopy [65] 50- 499 15 minutes/ slide# Yes Yes Yes $ 
RDT Immunochromatographic lateral 
flow assay& [8] 
200 15- 20 minutes/test* Yes Yes Yes $ 
PCR Ultrasensitive qPCR [32] 0.022 (blood) 40 samples/ day (manual) 
140 samples/day 
(automated) 
Yes No No $$ 
 Multiplex Malaria Sample Ready 
[34] 
0.244 (blood) Uncertain Uncertain Uncertain Yes  $$ 
 Mobile PCR [35] 2 (DBS) 96 well plate,  240 samples/ 
day 
Uncertain Yes Yes $$ 
 PET-PCR [37, 38] 
 
3.2 (blood) 
 
Real-time PCR platform, 
presumed 72 samples 
Uncertain Yes No ? 
 Gelcycler [39] 2 (blood) 12 Yes Yes No $ 
 Multiplex microarray assay [40] Uncertain Uncertain Yes Uncertain No $$ 
 CLIP-PCR [42] 0.3 (DBS) 96 well plate + pooled DBS Yes Yes No $ 
LAMP RealAmp [58] 0.4-40 (blood) 8 tubes Yes Yes Yes $$ 
 HtLAMP [57] 2.5 (blood) 96 well plate Yes No Yes $ 
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† $ < $US2; $$ > $US2, ? = cost unknown; & Malaria Rapid Diagnostic Test Performance- results of WHO product testing of malaria RDTs Round 5 (2013); # WHO 
Malaria Microscopy Quality Assurance Manual Version 1, 2009;*CDC website ww.cdc.gov/malaria/malaria_worldwide/reduction/dx_rdt.html. DBS = dried blood spot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LAMP-LFD [60] Uncertain 1.5 hour/test Yes No No ? 
 NINA-LAMP [63] Uncertain 5 tubes Yes Yes Yes ? 
 LoopAmp [51] 5 (blood) 16 Yes Yes Yes ? 
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Hypothesis and Aims 
 
Hypothesis  
Based on the aforementioned limitations to the diagnostic tools currently available for the 
purpose of malaria elimination, the hypothesis tested in this thesis was that loop mediated 
isothermal amplification (LAMP) could be used to develop a molecular diagnostic platform to 
support malaria elimination purposes. Therefore, the overall goal of this thesis was to develop 
a LAMP platform that was simple, cost effective and had the capacity to increase throughput 
while being amenable to application in resource limited settings. 
 
Aim 1: Optimise LAMP into a high-throughput assay 
Based on a review of existing LAMP platforms, I aimed to develop a LAMP platform that was 
capable of processing a large number of sample simultaneously using readily available, cost 
effective consumables. Then using published LAMP primers for Plasmodium falciparum and 
Plasmodium genus, I aimed to evaluate how the use of several cost effective, non commercial 
DNA extraction processes, on both filter paper and whole blood, would affect the analytical 
sensitivity of the assay. 
 
Aim 2: Compare the high-throughput LAMP (HtLAMP) platform to microscopy, rapid 
diagnostic tests (RDTs) and PCR for diagnosing mixed malaria species infections 
Given that the overall goal of the thesis was to develop a molecular diagnostic tool that could 
be used in resource limited settings, I aimed to compare the performance of HtLAMP with the 
currently available field diagnostic modalities of microscopy and RDTs as well as the most 
sensitive reference laboratory diagnostic modality of PCR using sample sets from areas of 
different parasite prevalence and different proportions of P. falciparum and P. vivax.  
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Aim 3: Develop HtLAMP as a species specific diagnostic platform for the sensitive 
detection of P. vivax and P. knowlesi 
In order for a molecular diagnostic tool to be useful for the purpose of malaria elimination, 
ideally it should have the capacity for species-specificity. Given the particular challenges 
posed by P. vivax and the lack of sensitive LAMP platforms for its specific diagnosis, I aimed 
to develop novel P. vivax specific LAMP primers to be used in the HtLAMP platform.  
For reliable detection of P. knowlesi, microscopy and RDTs lack sensitivity, particularly at low 
parasitemia. Therefore I aimed to use the HtLAMP platform for the detection of P. knowlesi by 
developing novel species specific P. knowlesi LAMP primers. 
 
Aim 4: Validate the field-applicability of the HtLAMP assay 
The overall goal of the thesis was to develop a molecular diagnostic tool that could be 
performed in resource limited settings for the purpose of malaria elimination. Therefore, 
having developed the HtLAMP platform and species-specific primers, I then aimed to evaluate 
its performance in a resource limited laboratory setting, in terms of logistics, feasibility and 
diagnostic accuracy compared with PCR. 
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Chapter 3  
Optimisation of Loop mediated isothermal amplification (LAMP) 
into a high-throughput, simple, colourimetric platform 
 
As described in Chapters One and Two, LAMP is an isothermal platform that has the potential 
to be performed in resource limited settings. There have been several LAMP platforms 
evaluated for malaria diagnosis. However, each has specific limitations with regards to either 
their ability to detect low level parasitemia, to be performed in field settings or their capacity 
for high throughput. 
One of the aims of this thesis was to use LAMP to develop a diagnostic tool, using readily 
available consumables, that was capable of processing large numbers of samples 
simultaneously for the purpose of malaria diagnosis. 
This chapter details the optimisation of a simple 96 well microtitre plate platform into a high 
throughput, colourimetric, field applicable LAMP platform. In order to improve the turnaround 
time of the assay, I also evaluated the performance of this high-throughput platform using 
DNA extracted from whole blood and filter paper blood spots using low cost extraction 
modalities. The high-throughput LAMP platform was then validated in a resource limited 
laboratory setting in Kota Marudu, Sabah, Malaysia to demonstrate its capacity for field 
applicability. 
The optimisation and validation of this high throughput LAMP platform (HtLAMP) was 
published in the Malaria Journal. 
Britton S, Cheng Q, Sutherland CS, McCarthy JS. A simple, high throughput, colourimetric, 
field applicable Loop mediated isothermal amplification (LAMP) assay for malaria elimination, 
Malaria Journal 2015, 14:335
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Abstract  
 
Background 
To detect all malaria infections in elimination settings sensitive, high throughput and field 
deployable diagnostic tools are required. Loop-mediated isothermal amplification (LAMP) 
represents a possible field-applicable molecular diagnostic tool. However, current LAMP 
platforms are limited by their capacity for high throughput.  
 
Methods 
A high-throughput LAMP (HtLAMP) platform amplifying mitochondrial targets using a 96-well 
microtitre plate platform, processing 85 samples and 11 controls, using hydroxynaphtholblue 
as a colourimetric indicator was optimized for the detection of malaria parasites. Objective 
confirmation of visually detectable colour change results was made using a 
spectrophotometer. A dilution series of laboratory-cultured 3D7 Plasmodium falciparum 
parasites was used to determine the limit of detection of the HtLAMP assay, using P. 
falciparum (HtLAMP-Pf) and Plasmodium genus (HtLAMP-Pg) primers, on whole blood and 
filter paper, and using different DNA extraction protocols. The diagnostic accuracy of HtLAMP 
was validated using clinical samples from Papua New Guinea, Malaysia, Ghana and The 
Gambia and its field applicability was evaluated in Kota Marudu district hospital, Sabah, 
Malaysia. 
 
57 
 
Results 
The HtLAMP assay proved to be a simple method generating a visually-detectable blue and 
purple colour change that could be objectively confirmed in a spectrophotometer at a 
wavelength of 600nm. When compared with PCR, overall HtLAMP-Pg had a sensitivity of 
98% (n= 260/266, 95% CI 95-99) and specificity 83% (n= 15/18, 95% CI 59-96).  HtLAMP-Pf 
had a sensitivity of 97% (n= 124/128, 95% CI 92-99) and specificity of 96% (n= 151/157, 95% 
CI 92-99). A validation study in a regional hospital laboratory demonstrated ease of 
performance and interpretation of the HtLAMP assay. HtLAMP-Pf performed in this field 
setting had a sensitivity of 100% (n=17/17, 95% CI 80-100) and specificity of 95% 
(n=123/128, 95% CI 90-98) compared with multiplex PCR. HtLAMP-Pf also performed well on 
filter paper samples from asymptomatic Ghanaian children with a sensitivity of 88% (n= 23/25, 
95% CI 69-97).   
 
Conclusion 
This colourimetric HtLAMP assay holds much promise as a field applicable molecular 
diagnostic tool for the purpose of malaria elimination. 
 
Keywords Loop mediated isothermal amplification, LAMP, elimination, high throughput, 
diagnosis, malaria
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Background 
Malaria elimination is an ambitious but enticing goal. Elimination is defined as “interrupting 
local mosquito-borne malaria transmission in a defined geographical area, ie zero incidence 
of locally contracted cases, although imported cases will continue to occur” [1]. By definition, 
malaria elimination is fundamentally different from malaria control, as the focus shifts from 
detection of symptomatic patients to detection and clearance of all infections. This includes 
active case detection of asymptomatic persons with sub-patent parasitaemia [2], subjects who 
have been shown to be able to support ongoing malaria transmission [3].  
 
For Plasmodium falciparum and Plasmodium vivax, passive and active detection of infection 
in the field have relied on two diagnostic tools: thick and thin blood film microscopy, and 
immunochromatographic detection of circulating parasite antigens using rapid diagnostic tests 
(RDT). While expert microscopy has been shown to have 100% sensitivity at thick film 
parasite densities of 50 parasites/ µL, sensitivity decreases significantly under operational 
field conditions [4]. Furthermore, studies in both Africa and Asia show that microscopy alone 
will fail to identify a substantial proportion of asymptomatic infections caused by all 
Plasmodium species, compared to detection by PCR [3]. It has been suggested that the 
proportion of submicroscopic infections is greater in areas where malaria elimination 
programmes are in place [5].  Such infections remain transmissible, and thus pose a threat to 
malaria elimination [6]. The success of malaria elimination programs will, therefore, critically 
depend on successful identification and treatment of all infected individuals. This requires 
high performance diagnostic tools, as outlined by the malERA consultative group [7]. The 
target sensitivity has recently been updated by WHO to specify a detection limit of 2 
parasites/ µL [8], a level substantially lower than expert microscopy. 
 
Loop-mediated isothermal amplification (LAMP) is a nucleic acid detection technology that 
has the potential to significantly improve malaria field diagnostics, particularly in elimination 
settings. LAMP differs from PCR in several critical ways. Firstly, it is an isothermal process 
relying on the Bacillus stearothermophilus (Bst) polymerase enzyme. It does not require the 
cyclical temperature changes [9] necessary for PCR. This facilitates field adaptation of LAMP 
platforms. Secondly, a positive LAMP reaction results in the formation of a magnesium 
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pyrophosphate precipitate which can be visually detected, by turbidimetry [9] or using metal 
ion indicators, such as calcein [10], hydroxynaphthol blue [11] and pico-green [12]. LAMP end 
products have also been visualized using melt curve analysis [13], a bioluminescent output in 
real time (BART) [14], a lateral flow dipstick [15] and a portable fluorescence detection unit 
(realAmp) [16]. 
 
Since its first description in 2001[9] LAMP has been applied to the detection of a wide variety 
of bacterial [17, 18], viral [19], fungal [20] and parasitic [21] organisms, in particular to 
facilitate diagnosis of infection in resource limited settings. There has been a significant 
amount of research effort invested into adapting LAMP for diagnosis of malaria. LAMP has 
been used for the detection of P. falciparum using crudely extracted DNA from whole blood 
[22], or using a rapid boil and spin method [23]. Subsequently, LAMP has been used to 
identify all Plasmodium species [24] including Plasmodium knowlesi [25, 26], and LAMP 
primers have been optimized to improve the sensitivity with which P. falciparum [23, 27] and 
P. vivax [28, 29] can be detected. Commercially available Loopamp kits (Eiken Chemical co) 
have been validated for detection of P. falciparum [30], including low density infections [31] 
and for the indirect detection of P. vivax using a combination of pan-genus and P. falciparum-
specific LAMP primers [32]. However, as Hsiang et al. noted, obtaining a high throughput 
LAMP assay would appear to be an important step in making the technology more widely 
applicable [33] for the purpose of malaria elimination. Although assay time for most LAMP 
platforms is rapid at 60- 90 minutes, sample throughput is restricted by the platform used. For 
example, the LoopAmp kits (Eiken chemical co) used in the turbidimeter (Eiken chemical co) 
has a capacity of only 16 samples, while the kits used with a heatblock and ultraviolet lamp 
has capacity of 46 samples [34]. The demonstration that colorimetric detection of LAMP 
products provides acceptable diagnostic accuracy [11] suggests that this could be adapted to 
produce a multi-well, low-cost format for the detection of malaria parasites by LAMP. 
 
This paper describes development of a platform for malaria LAMP that increases the 
throughput of the assay, and simplifies DNA extraction and sample analysis, resulting in 
improved field applicability. Validation of the platform was carried out by investigating its 
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diagnostic accuracy using PCR as a gold standard as it is highly sensitive and widely 
available in reference laboratories for detecting low-level parasitaemia.  
 
Methods 
 
Plasmodium parasite and clinical samples 
A 10-fold dilution series of laboratory-cultured 3D7 P. falciparum parasites was prepared in 
50% haematocrit blood using initial samples with parasitaemia adjusted to 1% and 0.5%, as 
determined by microscopic examination of thin blood films. The number of parasites per 
microlitre was calculated using an estimate of 5 x 106 red cells/ µL to create a dilution series 
of samples ranging from 5,000 to 0.5 parasites/ µL. Four 5 µL blood spots at each dilution 
were dried for 48 hours on blotting paper (Whatman 3MM) before being stored at 4°C with 
desiccant. Whole blood was stored at -20°C.  
For assay validation, clinical samples were retrospectively made available from the following 
clinical trials: 1) filter paper samples (n= 25) from asymptomatic children from Ghana [35], 2) 
whole blood samples (n= 97) from symptomatic children from The Gambia [36], 3) filter paper 
samples (n= 42) from symptomatic persons from a high prevalence malaria region in Papua 
New Guinea (PNG) and 4) filter paper samples (n= 145) from a case-control study [37] 
undertaken in region of mixed malaria species infections in Sabah, Malaysia. The inclusion 
and exclusion criteria for each of these studies are outlined in their respective publications. 
 
The study protocols for each study were approved by the Ghana Health Service Ethics 
Committee (proposal # GHS-ERC-08/7/10) and the Ethics Committee of the London School 
of Hygiene and Tropical Medicine (proposal # 5775), Joint Gambia Government/Medical 
Research Council Ethics Committee (re. 2002/910), QIMR Berghofer Medical Research 
Institute Human Research Ethics Committee (P2119), the Malaysian Medical Research Ethics 
Committee and Menzies School of Health Research, respectively. 
 
DNA extraction from filter paper 
The chelex method for DNA extraction from filter paper [38] was further optimized to improve 
turnaround time. Briefly, 6mm filter paper disc punches, corresponding to 5 µL of blood, were 
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incubated in 0.5 % saponin in PBS either overnight (chelex standard protocol) or for 2 hours 
(chelex rapid protocol), centrifuged for 2 minutes at 4000 rpm, supernatant discarded, washed 
in PBS, centrifuged for 2 minutes at 4000 rpm, heated at 98°C in 150 µL of 6 % chelex 
(Sigma Aldrich, CAS 8047-15-2) for 30 minutes and centrifuged for 3 minutes at 4,000 rpm. 
The resultant 100 µL supernatant was stored at -20°C. 
 
DNA extraction from whole blood 
For whole blood, the chelex method [39] was further evaluated in two modified protocols. 
Briefly, 5 µL of whole blood was mixed with either 200 µL of nuclease-free water for 20 
minutes at room temperature (WB-chelex protocol) or 200 µL of 0.5% saponin, and incubated 
at 37°C for 30 minutes (WB-chelex saponin protocol). Samples were then centrifuged for 3 
minutes at 10, 000 rpm, supernatant discarded, the pellet heated at 98°C in 150 µL of 6% 
chelex for 30 minutes and centrifuged for 3 minutes at 10,000 rpm. The resultant supernatant 
was stored at -20°C. For both extraction protocols, three volumes of blood, 5 µL, 10 µL and 
20 µL, were assessed.   
 
DNA extraction from clinical samples 
The Gambia whole blood samples were extracted using the WB-chelex protocol on 5 µL of 
blood. The filter paper samples from Ghana were extracted using the FP-chelex standard 
protocol. The PNG and Sabah filter paper samples were extracted using the FP-chelex rapid 
protocol. The differences in methods used for clinical sample processing reflect the different 
sample sets used to validate each of the extraction protocols. 
 
 High-throughput LAMP (HtLAMP) method 
High throughput (HtLAMP) was performed in a 96-well microtitre plate as described [11], with 
some modifications. The assays were performed in a standard u-bottom microtitre plate 
(Sterihealth) covered with a clear disposable plate cover (Eppendorf).  Each plate was able to 
process 85 samples allowing for 9 negative and 2 positive controls. Reactions were 
performed in 25 µL total volume containing 1X buffer (20 mM Tris HCL pH 8.8, 10 mM KCl, 8 
mM MgSO4, 10 mM NH4SO4), 1.25 mM each dNTP, 3.55 µM each Pf869FIP/ BIP, 1.78 µM 
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each Pf869LF/ LBn, 0.2µM each Pf869F3/ B3, 1.18 µM each PgID19FIP/BIP, 0.59 µM each 
PgID19 LF/LB and 0.15 µM each PgID19 F3/B3, 120 µM Hydroxynaphthol-blue (Fluka, CAS 
number 63451-35-4) and 8 units Bst polymerase (New England Biolabs, Ipswich, MA). Primer 
sequences for Pf869 and PgID19 were as published by Polley et al. [23] except Pf869LBn 
GTTGAGATGGAAACAGCCGG. Microtitre plates were incubated in a water bath at 65°C for 
40 minutes before the colour change and precipitate in each well were recorded. Blue colour 
change with a visible precipitate was read as a positive result and purple colour change 
without a precipitate was read as a negative result (Figure 3.1). Positive and negative 
samples were read by a single person who was blinded to the multiplex PCR results for the 
samples being analysed. 
 
Performance of HtLAMP in a laboratory setting with limited resources involved storing 
reagents in a freezer at -20°C and preparation of the mastermix as required for performance 
of each HtLAMP assay. Efforts to prevent contamination were based on physical separation 
of DNA extraction from mastermix preparation areas and spectrophotometry, combined with 
stringent attention to hand hygiene and glove and gown changes between the different assay 
areas.  
 
Limit of detection of HtLAMP 
The limit of detection (LOD) for the HtLAMP assay was determined by performing HtLAMP-Pg 
and HtLAMP-Pf on duplicate samples at each dilution. Filter paper extracted using the two 
DNA extraction protocols and whole blood 5 µL, 10 µL and 20 µL extracted using the two 
DNA extraction protocols were evaluated. The LOD was determined to be the lowest dilution 
(containing the least parasite material) at which both duplicates were positive by HtLAMP. 
 
Factors affecting Hydroxynaphthol blue (HNB) 
HNB is a metal ion indicator that is sensitive to changes in pH as well as concentrations of the 
divalent cations magnesium and calcium. Using pH calibration buffers at pH 4.0, 7.0 and 10.0 
plus hydrochloric acid, 8 samples of different pH were produced and tested with HNB. 
Resulting colour changes were recorded visually. Magnesium sulphate (MW 246.68 g/mol) 
and calcium chloride (MW 110.99 g/mol) were used to make 5 samples of concentrations 
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varying from 1M to 0.001M. These were also tested with HNB and resulting colour changes 
were recorded visually. 
 
Spectrophotometer for determining threshold of positive result 
A plate spectrophotometer (PowerwaveXS2 software version 2.00.18) was used in order to 
determine a threshold value to objectively differentiate a positive from a negative HtLAMP 
result and demonstrate the reliability of visually detectable colour change in determining a 
positive and negative sample.  Using a P. falciparum 3D7 DNA dilution series, HtLAMP 
mastermix reagents both with and without HNB were placed in the microtitre plate. Nuclease 
free water was used as the no template negative control. Following incubation in a water bath 
at 65°C for 40 mins, the microtitre plate was read visually to document cloudy and blue 
positive reactions and clear and purple negative reactions in the wells containing HNB. The 
presence and absence of cloudy white precipitate was recorded in the wells without HNB. The 
microtitre plate was then read in the spectrophotometer across the visible light spectrum from 
300-700 nm to identify the wavelengths that best discriminated positive and negative samples 
both with and without HNB. 
 
The optical density (OD) value with the best discrimination of HNB related positive and 
negative colour change as well as presence and absence of magnesium pyrophosphate 
precipitate was then used to read each well. The threshold value for a positive reaction was 
calculated using the mean plus two standard deviations of the no template control (NTC) 
wells. This threshold value was then subtracted from the OD reading for each well to obtain a 
positive or negative numerical value. The presence of a visible blue colour change with 
presence of cloudy precipitate was mandatory for a sample to be positive. A positive 
numerical OD value was used to confirm the visually determined positive result. A sample that 
was purple and clear was considered a negative result with a negative OD value confirming 
this result. Samples with only a positive OD result without corresponding colour change and 
precipitate were considered negative. Therefore, results were recorded based on their colour 
change with OD values being used to confirm the visually detected result. Only samples with 
the appropriate colour change and corresponding OD result were considered true positives or 
true negatives for the purpose of statistical analysis.  
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Nested PCR 
For both whole blood and filter paper DNA extraction methods, the limit of detection was 
determined by comparison of HtLAMP to nested PCR as described by Snounou et al. [40]. 
PCR reactions were performed in 20 µL total volume containing 1X buffer, 2 mM MgCl2, 200 
µM dNTPs, 200 µM primer mix (rPLU5new/rPLU6 for nest 1 and rFAL1/rFAL2 for nest 2) and 
0.5 U Taq polymerase (Bioline). The PCR amplification products were visualized by gel 
electrophoresis. 
 
Multiplex PCR 
PCR was used as the reference standard for analysing the diagnostic accuracy of the 
HtLAMP platform given its sensitivity. Multiplex PCR (mPCR), which has an LOD of 0.02- 
0.05 parasites/ µL as described by Padley et al. [41] and had already been performed on 
these samples as part of their respective studies, was used as the gold standard reference 
test for comparison of HtLAMP-Pf and HtLAMP-Pg in the analysis of the PNG and Sabah 
samples. Nested PCR [40] was performed on the Ghana and Gambia samples. 
 
Statistics 
Sensitivity and specificity of HtLAMP was calculated against mPCR and nested PCR. 
Sensitivity = true positives/(true positives + false negatives) and specificity = true negatives 
/(true negatives + false positives). The 95% confidence intervals were calculated using an 
online calculation tool [42]  
 
Feasibility of field application of htLAMP 
The HtLAMP assay field applicability was assessed by performing the assay in a regional 
hospital in Kota Marudu district in Sabah, Malaysia. DNA was extracted from filter paper 
samples of 145 symptomatic patients using the FP-chelex rapid protocol, assayed using 
HtLAMP-Pg and HtLAMP-Pf and resulted were interpreted visually and confirmed with a 
portable spectrophotometer. Following a three-day training workshop for local malaria staff on 
performance and interpretation of HtLAMP assay results, a questionnaire was completed on 
challenges of performing the HtLAMP assay in a regional laboratory setting. 
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Results 
 
Limits of detection of HtLAMP 
The HtLAMP limit of detection was dependent on sample type, ie whole blood or filter paper, 
DNA extraction method and the LAMP primer used (Plasmodium genus primers PgID19 or P. 
falciparum primers Pf869 [23]) (Table 3.1). In the HtLAMP platform, overall, the Plasmodium 
genus LAMP primers (HtLAMP-Pg) performed with a better analytical sensitivity than the P. 
falciparum LAMP primers (HtLAMP-Pf). For whole blood 10 µL and 20 µL, the chelex-saponin 
DNA extraction protocol resulted in better analytical sensitivity compared to using chelex 
alone. The explanation for the discrepancy in results for whole blood 5 µL for the two 
extraction protocols are unclear but may include pipetting error of blood at small volumes and 
partial loss of red cell pellet during the DNA extraction process. The best analytical sensitivity 
for HtLAMP-Pg was achieved using 10 µL of whole blood with the WB-chelex saponin 
protocol. This had a LOD of 2.5 parasites /µL which was equal to the nested PCR used. The 
best LOD for HtLAMP-Pf was 5 parasites /µL using 20 µL of whole blood with the WB-chelex 
saponin protocol. This was equal to the LOD for HtLAMP-Pg at this volume, while nested 
PCR had an LOD of 0.5 parasite /µL. 
 
For filter paper, the standard chelex protocol, with an overnight incubation step performed 
better than the rapid protocol with a 2 hour incubation step, providing a 10-fold lower (LOD) 
for HtLAMP-Pg, ie 2.5 parasites /µL compared to 25 parasites /µL. For filter paper samples, 
the LOD for HtLAMP-Pg using the FP-standard chelex protocol for DNA extraction was 2.5 
parasites /µL, while the sensitivity of HtLAMP-Pg using the FP-rapid chelex protocol was 25 
parasites /µL. The HtLAMP-Pf assay was able to detect 5 parasites /µL using the FP-standard 
chelex protocol and 50 parasites /µL using the FP-rapid chelex protocol. Therefore, the FP 
rapid chelex protocol appears to trade-off analytical sensitivity for a faster turnaround time for 
the assay. Taken together, these results confirm that the starting sample material and method 
of DNA processing have important effects on the analytical sensitivity of the HtLAMP assay. 
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In the interest of improving turnaround time of the assay the FP- rapid chelex protocol was 
chosen despite a compromise in analytical sensitivity for the validation of the HtLAMP 
platform on filter paper samples from PNG and field testing in Sabah. 
 
Optimal wavelength for developing an objective threshold for positive results 
When interrogated across the visible spectrum of light, wavelengths between 600-650nm, 
appeared to best distinguish positive from negative samples, whether the cloudy magnesium 
pyrophosphate precipitate was present or not and whether there was a blue or purple colour 
change associated with HNB (Figure 3.2). The wavelength of 600nm was chosen to provide 
OD values for the HtLAMP assay for the following reasons; a) this value produced OD values 
that discriminated well between cloudy and blue positive HtLAMP reactions and clear and 
purple negative samples in order to calculate an objective OD threshold for each plate of 
samples and b) a 600nm filter is a standard setting for many bench top spectrophotometers.  
Table 3.4 shows the correlation between the visually detected colour change and 
corresponding OD-derived threshold values for the interpretation of HtLAMP-Pf results for a 
subset of samples from the field validation study in Sabah. 
 
Effect of pH, magnesium sulphate and calcium chloride on HNB colour change 
The colour change associated with HNB was significantly affected by changes in pH, 
magnesium and calcium. At pH 3, HNB had a pink appearance compared with dark blue at 
pH 7 and sky blue at pH 10. Colour variation was also seen with magnesium, ranging from 
pink at a concentration of 0.001 M concentration to dark purple at a concentration of 1.0 M, 
and calcium, from dark pink at 0.01 M concentration to bright blue at 0.5 M concentrations. 
This suggests that maintaining the correct concentration of calcium, magnesium and pH of 
the mastermix, as well as awareness of other metal ions present during extractions 
processes, is important in allowing HNB to undergo its colour change during a LAMP reaction. 
 
Sensitivity and specificity of HtLAMP-Pg and HtLAMP-Pf in clinical samples from symptomatic 
patients for the detection of P. falciparum  
Filter paper blood spots from symptomatic patients from Papua New Guinea and Sabah, 
Malaysia and whole blood samples from The Gambia were evaluated using HtLAMP-Pg and 
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HtLAMP-Pf to determine the diagnostic accuracy of the assay for the detection of P. 
falciparum. The features of each of these sample sets and composite sensitivity and 
specificity of HtLAMP-Pg/Pf for the detection of P. falciparum are outlined in Table 3.2. 
 
Overall, HtLAMP-Pg had a sensitivity of 98% (n= 260/266, 95% CI 95-99) and specificity of 
83% (n= 15/18, 95% CI 59-96) for the detection of Plasmodium species. HtLAMP-Pf had a 
sensitivity of 97% (n= 124/128, 95% CI 92-99) and specificity of 96% (n= 151/157, 95% CI 92-
99) for the detection of P. falciparum.  
 
Sensitivity and specificity of the combination of HtLAMP-Pg and HtLAMP-Pf for the detection 
of non-falciparum Plasmodium mono-infection in symptomatic patients 
The diagnostic accuracy of the combination of HtLAMP-Pg and HtLAMP-Pf for the detection 
of non-falciparum Plasmodium species mono-infections was also assessed. In this context, 
the sensitivity of HtLAMP-Pg was 100% (n=232/232, 95% CI 98-100), with a specificity of 
83% (n=15/18, 95% CI 56-96).  
 
Subgroup analysis demonstrated that in the Papua New Guinea samples, HtLAMP-Pg had a 
sensitivity of 100% (n= 9/9, P. vivax positive) and specificity of 81% (n= 13/16). There were 3 
false positive HtLAMP-Pg results. HtLAMP-Pf was negative in all the mono-infection samples. 
For the 128 non-falciparum species infections from Sabah, HtLAMP-Pg had a sensitivity of 
100% (n= 128/128). HtLAMP-Pf was negative for 122 of these samples. For the 6 false 
positive HtLAMP-Pf results (five P. vivax, one P. knowlesi) there was no evidence of P. 
falciparum co-infection by PCR. In the Gambia samples, of the 95 HtLAMP-Pg positive 
samples, only 1 was negative by HtLAMP-Pf, suggesting a non-falciparum species mono-
infection which was confirmed by PCR to be Plasmodium malariae with a parasitaemia of 7.5 
parasites /µL.  
 
Sensitivity of HtLAMP in persons with asymptomatic parasitaemia 
Features of the 25 samples chosen from a set of samples from asymptomatic school children 
in Kumasi, Ghana are outlined in Table 3.6. Of the 25 samples 100% were positive for P. 
falciparum by nested PCR and 44% were co-infected with P. malariae. Interestingly, HtLAMP-
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Pg was positive for two samples in which only P. falciparum gametocytes were seen on 
microscopy of which one was also positive by HtLAMP-Pf.  Compared with nested PCR the 
sensitivity of HtLAMP-Pg was 96% (n=24/25, 95% CI 80-100) and sensitivity of HtLAMP-Pf 
was 88% (n=22/25, 95% CI 69-97)(Table 3.3). HtLAMP-Pg and HtLAMP-Pf were able to 
detect the samples with the lowest parasitaemia of 40 parasites/ µL (n=3). 
 
Feasibility of field application of HtLAMP 
HtLAMP was performed in a regional hospital laboratory in Kota Marudu district, Sabah, 
Malaysian Borneo. This laboratory was able to perform basic haematology and biochemistry 
testing but did not perform microbiological culture or molecular assays. The HtLAMP assay 
was performed in a plastic bucket adapted to function as a water bath using a heating 
element and thermometer. A portable spectrophotometer (ChroMate) with a 600nm filter 
provided the optical densitometry values. Samples and HtLAMP reagents were stored at -
20°C in a freezer. Three separate benches within a large room were dedicated to DNA 
extraction, HtLAMP assay setup and spectrophotometry in order to prevent cross-
contamination.  
 
The HtLAMP-Pg assay, performed in this resource-limited laboratory setting, had a sensitivity 
of 100% (n= 145/145, 95% CI 97-100). The HtLAMP-Pf assay had a sensitivity of 100% (n = 
17/17, 95% CI 80-100) and a specificity of 95% (n = 123/128, 95% CI 90-98).  
 
Two local malaria laboratory staff was trained over a 3 day period to perform DNA extraction 
from filter paper and whole blood, setup the assay and interpret the results of the HtLAMP 
assay. Issues that were identified by local staff as potential limitations to deployment of 
HtLAMP in a field laboratory were difficulty of accurate sample placement into the 96-well 
plate and the availability and cost of reagents. However, it was felt that these limitations were 
balanced against the rapid turnaround time for the detection of parasites in microscopy 
negative samples thereby facilitating earlier patient treatment and household screening, 
potential time and cost saving in avoiding sending samples for PCR testing at reference 
laboratories and ease of interpretation of visual colour change results on the HtLAMP assay. 
The main challenges to setting up HtLAMP in this non-reference, low resource setting 
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laboratory were ensuring good workflow to prevent contamination, and ensuring the reliability 
of ancillary equipment such as the centrifuge and freezers.  
 
Discussion 
To achieve its ambitious goals, the malaria elimination agenda will likely require diagnostic 
capacity to actively identify sub-patent infection in order to interrupt transmission. PCR, the 
most sensitive molecular diagnostic tool currently available, is limited by its technical 
requirements, particularly in resource limited field settings. A robust, low-cost and high-
throughput assay for the rapid detection of malaria parasite DNA in finger-prick blood samples 
would provide this capacity. 
  
LAMP has been adapted into several different platforms [16, 34, 43-45] in order to improve its 
field applicability and throughput. While the definition of the throughput required for the 
application of LAMP for the purpose of malaria elimination remains to be established, the 
number of samples able to be processed simultaneously on these platforms range from 5 [43] 
to 46 [34] per assay. 
 
The HtLAMP assay for the diagnosis of malaria that is described here has a simple platform- 
a standard 96-well microtitre plate, covered with a clear plate seal and incubated in a water 
bath at 65°C that is able to process a minimum of 85 samples (allowing for positive and 
negative controls). The use of a colorimetric indicator enhances visual detection of the assay 
endpoint. To improve objectivity of interpretation of results, the assay uses a 
spectrophotometer at 600nm to produce a threshold value which correlates with the visible 
colour change. In addition, DNA extraction protocols for whole blood and filter paper based on 
chelex and saponin have been modified to improve turnaround time while maintaining the 
cost effectiveness of the assay. 
 
However, there appears to be significant variation in the LOD of HtLAMP depending on 
sample type, DNA extraction method and primers selected, particularly so for filter paper 
samples where there was a ten-fold loss of analytical sensitivity using a DNA extraction 
method that had a faster turnaround time. Nevertheless, HtLAMP-Pg using 10 µL of whole 
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blood with a chelex saponin protocol and HtLAMP-Pg on a 5 µL filter paper blood spot using 
the chelex overnight protocol achieved a LOD of 2.5 parasites/ µL. This suggests that the 
HtLAMP platform has the potential to reach the WHO target LOD. However, further 
modifications, such as using commercial kits, optimisation of low cost DNA extraction 
methods or using a larger volume of blood are likely to be required to achieve the balance 
between improved analytical sensitivity and turnaround time. The availability of more sensitive 
LAMP primers to detect Plasmodium genus and species- specific primers may also enhance 
the LOD of the HtLAMP assay. Therefore, malaria elimination programs choosing diagnostic 
tools may be required to make important operational and logistics decisions with regards to 
both the type of assay used and the sample types, for example whole blood or filter paper, 
that can achieve the best analytical sensitivity for that assay in order to meet the current WHO 
target of 2 parasites/ µL.  
 
The HtLAMP assay has been validated in a resource limited laboratory setting using filter 
paper samples and the chelex rapid DNA extraction protocol, despite its aforementioned 
limitations, in order to evaluate its turnaround time in this clinical setting. Compared with PCR, 
which requires samples to be sent to a reference laboratory, HtLAMP-Pg had a sensitivity of 
100% and HtLAMP-Pf had a sensitivity of 100% and a specificity of 95% and results were 
available within 24 hours. 
 
In this study, the HtLAMP assay was validated for the detection of Plasmodium genus and P. 
falciparum on clinical samples from microscopy positive symptomatic and asymptomatic 
patients from regions with different Plasmodium species prevalence.  Overall, HtLAMP-Pg 
had a sensitivity of 98% and specificity of 83% and HtLAMP-Pf had a sensitivity of 97% and 
specificity of 96% for the detection of P. falciparum. The use of the combination of 
Plasmodium genus and P. falciparum LAMP primers showed a HtLAMP-Pg sensitivity of 
100% and specificity 83% compared to PCR for the detection of non-falciparum Plasmodium 
monoinfections. These results are comparable to other LAMP studies in symptomatic patients 
(Table 3.5). However, further studies are required to determine the sensitivity and specificity 
of HtLAMP in detecting sub-microscopic infections in asymptomatic patients. 
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The 96 well HtLAMP platform is able to test 85 samples per plate, allowing for positive and 
negative controls. The cost per test in this platform is USD$ 0.85 excluding primers and DNA 
extraction. Final cost will depend on the starting material (filter paper or whole blood), the use 
of either crude or commercial DNA extraction protocols and the primer sets selected. 
Nevertheless, the cost per sample to perform HtLAMP-Pg on whole blood extracted using 
chelex-saponin protocol is USD$1. The turnaround time for completion of an assay, including 
DNA extraction, is 4-6 hours. 
 
However, HtLAMP is not a quantitative assay, a limitation it shares with other LAMP based 
assays. Other potential limitations include the use of HNB, which is sensitive to changes in pH 
and metal ion concentrations. Awareness of, for example, the type of DNA extraction method 
used on samples, which may contain reagents that affect pH and metal ion concentrations, 
would help maintain the reliability of interpretation of the colour change aspect of the assay. 
Nevertheless, this is balanced against its low cost, stability at room temperature and easy 
visual interpretation of results. In its current format, HtLAMP relies on the storage of reagents 
at -20°C. While an important issue in terms of field deployment, this could potentially be 
overcome by lyophilisation of reagents. 
 
Conclusion 
 
The HtLAMP platform offers several important improvements over currently available LAMP 
platforms. Firstly, HtLAMP is able to process up to 85 samples simultaneously which makes it 
an ideal potential platform for surveillance or household surveys. Secondly, it uses standard 
consumables, and can be performed using DNA extracted by chelex and saponin based 
protocols which makes it very cost effective. Thirdly, one of the significant advantages to the 
use of HNB is that it can be added to the start of the assay such that HtLAMP remains a 
closed system, thereby reducing the risk of cross- contamination. Fourthly, while the platform 
of HtLAMP has been used here with Plasmodium genus and P. falciparum primers, it could 
be adapted to detect any other blood-borne pathogen of interest, thereby broadening the 
potential applications of the platform beyond the diagnosis of malaria. Finally, HtLAMP has 
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been performed successfully in a regional laboratory setting by local staff trained over a very 
short period of time demonstrating its ease of performance and interpretation of results.  
 
This provides confidence that the HtLAMP can be usefully deployed as a molecular diagnostic 
tool to support malaria elimination in resource-limited settings. 
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Figures 
Figure 3:1 HtLAMP colour change associated with hydroxynaphtholblue (HNB) 
Left: Clear, purple colour, without precipitate = negative 
Right: Blue colour change with cloudy precipitate = positive 
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Figure 3:2 Optical density values across the visible spectrum of light for HtLAMP samples 
with and without HNB 
Between the wavelengths of 550- 650nm higher optical densitometry readings were found for 
samples that were positive by HtLAMP (no HNB positive and HNB positive). In addition, at 
these wavelengths, the optical densitometry readings were also able to distinguish samples 
that were positive due to the presence of the magnesium pyrophosphate precipitate (no HNB 
positive) and samples that were by positive by HtLAMP due to the blue colour change 
associated (HNB positive). 
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 Table 3:1 Summary of limits of detection for HtLAMP-Pg and HtLAMP-Pf for whole blood and 
filter paper with different DNA extraction protocols 
Sample (n=4) DNA extraction 
protocol 
Limit of 
detection 
nested PCR 
(parasites/µL) 
Limit of 
detection 
HtLAMP-Pg 
(parasites/µL) 
Limit of 
detection 
HtLAMP-Pf 
(parasites/µL) 
Whole blood 5µL WB-chelex 
WB-chelex-saponin 
5 
25 
5 
50 
50 
50 
Whole blood 10µL WB-chelex 
WB-chelex-saponin 
2.5 
2.5 
25 
2.5 
50 
50 
Whole blood 20µL WB-chelex 
WB-chelex-saponin 
25 
0.5 
50 
5 
50 
5 
Filter paper 5µL Chelex standard 
protocol (overnight) 
Chelex rapid protocol 
(2 hours) 
2.5 
 
5 
2.5 
 
25 
5 
 
50 
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Table 3:2 Sensitivity and specificity of HtLAMP-Pg/Pf for the detection of P. falciparum 
This table summarizes the features of each of the 3 sample sets, from Papua New Guinea, Sabah Malaysia and The Gambia, and a 
composite sensitivity and specificity of HtLAMP-Pg/Pf for the detection of P. falciparum.  
 
Origin Assay Diagnostic 
accuracy 
 No. of 
samples 
Type of 
sample 
PCR technique 
used for 
speciation 
Pf Pv Pm Pk Po 
spp 
Mixed 
infections 
Negatives 
Papua New 
Guinea 
   42 Filter paper Multiplex PCR 12 9 0 0 0 5 (Pf/Pv) 16 
 HtLAMP-Pg 
 
Sensitivity 
 
77% (20/26)     
95% CI 56-91 
          
  Specificity 81% (13/16)     
95% CI 54-96 
          
 HtLAMP-Pf Sensitivity 76% (13/17)    
95% CI 50-93 
          
  Specificity 100% (25/25)  
95% CI 86-100 
          
Sabah, 
Malaysia 
   145 Filter paper Multiplex PCR and 
nested PCR (Pk) 
17 64 7 56 0 1 (Pv/Pk) 0 
 HtLAMP-Pg 
 
Sensitivity 
 
100% (145/145)  
95% CI 97-100 
          
 HtLAMP-Pf Sensitivity 100% (17/17)  
95% CI 80-100 
          
  Specificity 95% (123/128)  
95% CI 90-98 
          
The Gambia    97 Whole 
blood 
Nested PCR 94 NA 1 NA 0 0 2 
 HtLAMP-Pg 
 
Sensitivity 
 
100% (95/95)  
95% CI 96-100 
          
  Specificity 100% (2/2)       
95% CI 16-100 
          
 HtLAMP-Pf Sensitivity 100% (94/94)  
95% CI 96-100 
          
  Specificity 100% (3/3)      
95% CI 29-100 
          
TOTAL    284   124 73 8 56 0 6 18 
 HtLAMP-Pg 
 
Sensitivity 
 
98% (260/266)  
95% CI 95-99 
          
  Specificity 83% (15/18),  
95% CI 59-96 
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  PPV 99%,  
95% CI 97-100 
          
  NPV 71%, 95% CI 48-89           
 HtLAMP-Pf Sensitivity 97% (124/128)  
95% CI 92-99 
          
  Specificity 96% (151/157)  
95% CI 92-99 
          
  PPV 95%, 95% CI 90-98           
  NPV 97%, 95% CI 94-99           
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Table 3:3 Sensitivity and specificity of HtLAMP compared with nested PCR in Ghanaian 
children with asymptomatic parasitaemia 
 
 Sensitivity PPV 
HtLAMP-Pg (compared 
with nested PCR) 
96% (24/25) 
95% CI 80-100 
100% 
95% CI 85-100 
HtLAMP-Pf (compared 
with nested PCR) 
88% (22/25) 
95% CI 69-97 
100%  
95% CI 85-100 
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Table 3:4  HtLAMP-Pf optical densitometry (OD) results for 77 filter paper samples demonstrating the correlation between the visually detected 
colour change results for positive samples and their correlation with the positive results based on an OD-derived threshold value 
 
Samples in blue had a blue/cloudy colour change as well as a corresponding positive OD threshold value. Samples in yellow were positive only 
by OD threshold. Shaded grey wells were negative controls within the plate. OD values for all negative control samples in each plate are used to 
calculate the OD threshold value (mean plus two standard deviations) which in this example is 0.262.  
 
1 2 3 4 5 6 7 8 9 10 11 12
A 29 154 19 17 22 27 34 23 180 32 42 176 0.225
0.374 0.229 0.256 0.257 0.219 0.217 0.252 0.244 0.344 0.243 0.296 0.333 0.235
0.112 -0.033 -0.006 -0.005 -0.043 -0.045 -0.01 -0.018 0.082 -0.019 0.034 0.071 0.218
B 46 30 35 66 36 47 41 52 48 186 53 54 0.224
0.248 0.327 0.234 0.342 0.238 0.241 0.239 0.23 0.217 0.216 0.231 0.366 0.263
-0.014 0.065 -0.028 0.08 -0.024 -0.021 -0.023 -0.032 -0.045 -0.046 -0.031 0.104 0.215
C 65 51 72 73 62 84 67 70 90 74 92 0.208
0.232 0.246 0.232 0.225 0.338 0.333 0.256 0.224 0.246 0.366 0.228 0.31 0.243
-0.03 -0.016 -0.03 -0.037 0.076 0.071 -0.006 -0.038 -0.016 0.104 -0.034 0.048 0.225
D 77 96 81 85 194 89 100 101 95 68 106 0.239
0.231 0.217 0.248 0.217 0.226 0.243 0.235 0.257 0.357 0.22 0.317 0.236 0.242
-0.031 -0.045 -0.014 -0.045 -0.036 -0.019 -0.027 -0.005 0.095 -0.042 0.055 -0.026 0.262
E 159 122 131 124 127 94 136 129 105 187 142
0.248 0.218 0.221 0.225 0.225 0.212 0.312 0.208 0.213 0.304 0.227 0.211
-0.014 -0.044 -0.041 -0.037 -0.037 -0.05 0.05 -0.054 -0.049 0.042 -0.035 -0.051
F 137 147 149 189 141 112 146 157 112(1) 160 198
0.252 0.237 0.22 0.209 0.224 0.213 0.207 0.228 0.225 0.227 0.301 0.274
-0.01 -0.025 -0.042 -0.053 -0.038 -0.049 -0.055 -0.034 -0.037 -0.035 0.039 0.012
G 115 116 177 119 178 181 123 151
0.263 0.232 0.215 0.211 0.21 0.202 0.199 0.211 0.208 0.191 0.263 0.216
0.001 -0.03 -0.047 -0.051 -0.052 -0.06 -0.063 -0.051 -0.054 -0.071 0.001 -0.046
H pos pos NTC NTC NTC NTC
0.407 0.385 0.243 0.225 0.223 0.239 0.242 0.27 0.261 0.207 0.19 0.175
0.145 0.123 -0.019 -0.037 -0.039 -0.023 -0.02 0.008 -0.001 -0.055 -0.072 -0.087
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Table 3:5  Comparison of sensitivity and specificity of HtLAMP-Pg and HtLAMP-Pf for the 
detection of P. falciparum and non-falciparum species with other LAMP studies in 
symptomatic patients 
 
LAMP study Sample source Species LAMP primer Sensitivity (%)  Specificity 
(%) 
HtLAMP Symptomatic 
patients 
P. falciparum Pg 98 83 
   Pf 97 96 
Polley et al. 
2010 [23] 
Symptomatic 
patients 
P. falciparum Pg 93.9 100 
   Pf 93.3 100 
Polley et al. 
2013 [27] 
Symptomatic 
returned travellers 
P. falciparum Pg 97 99.2 
   Pf 98.4 98.1 
Hopkins et al. 
2013 [30] 
Passive case 
detection 
P. falciparum Pf 89- 93.9 76.3- 85 
HtLAMP Symptomatic 
patients 
Non-falciparum  Pg 100 83 
Vallejo et al. 
2015 [32] 
Symptomatic 
patients 
Non-falciparum Pg 91.4 91.8 
82 
 
Table 3:6 Features of asymptomatic Ghanaian children samples (n=25)  
Table outlines features of the 25 samples chosen from a set of samples from asymptomatic 
school children in Kumasi, Ghana.  
Features Details Numbers 
Age groups Less than 10 years old 
10-16 years old 
16 years and older 
10 
10 
5 
Microscopy results Asexual P. falciparum only 
Asexual P. falciparum and 
gametocytes 
P. falciparum gametocytes only 
P. malariae parasites 
21 
2 
 
2 
0 
Parasitemia by microscopy Range 
Number of samples with 
parasitemia <100 parasites /µL 
40- 5120 parasites /µL 
4 
Nested PCR results P. falciparum only (Pf) 
P. malariae only (Pm) 
Pf/ Pm co-infection 
14 
0 
11 
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Chapter 4  
High-throughput LAMP for the identification of  
Plasmodium vivax 
 
Plasmodium vivax, poses a significant challenge to malaria elimination for several important 
reasons. Firstly, the parasite’s lifecycle has a hypnozoite stage which can remain dormant in 
the human liver for months to years before re-emerging as symptomatic clinical infection 
during which transmission to mosquitoes can occur. At present, there are no diagnostic tools 
able to detect P. vivax hypnozoites. Secondly, treatment to clear P. vivax hypnozoites is 
limited to primaquine, which is an effective drug but carries a risk of severe hemolysis in 
persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency and requires a 14 day 
course of treatment which may compromise its effectiveness in the setting of patient non-
compliance. Thirdly, the extent of the submicroscopic reservoir of P. vivax appears to be 
much more extensive than previously appreciated and capable of transmission to the 
mosquito vector even at low levels of parasitemia. Therefore, from a malaria elimination point 
of view, the need for a sensitive, field applicable, molecular diagnostic tool for the detection of 
low level P. vivax parasitemia is pressing.  
There are currently three published sets of LAMP primers for the specific detection of P. 
vivax. However, these are limited in their ability to detect low level parasitemia with the best 
available assay being able to detect 125 parasites/ µL. Although the sensitivity of microscopy 
under field conditions reduces below 100 parasites/ µL, expert microscopy has a sensitivity of 
around 50 parasites/ µL. Therefore, the sensitivity of a P. vivax specific LAMP assay would 
need to be below 50 parasites/ µL in order to be able to detect the reservoir of 
submicroscopic P. vivax infected patients. 
This chapter pertains to the development and validation of novel, sensitive P. vivax LAMP 
primers targeting a mitochondrial gene. Used in the HtLAMP platform, described in Chapter 
Three, the limit of detection of this HtLAMP-Pv assay was 1.4 parasites/ µL. Although these 
primers cross reacted with P. knowlesi due to the 97% sequence identity at the target gene 
site, this is likely to be a limiting factor in only a select geographical region within south-east 
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Asia where P. knowlesi is known to co-exist with P. vivax. Furthermore, this HtLAMP-Pv 
assay has been validated in asymptomatic patients with P. vivax malaria as well as on 
symptomatic patients in a resource limited laboratory setting and the results were published in 
the PloS Neglected Tropical Diseases journal. 
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Abstract 
Introduction 
Plasmodium vivax malaria has a wide geographic distribution and poses challenges to 
malaria elimination that are likely to be greater than those of P. falciparum. Diagnostic tools 
for P. vivax infection in non-reference laboratory settings are limited to microscopy and rapid 
diagnostic tests but these are unreliable at low parasitemia. The development and validation 
of a high-throughput and sensitive assay for P. vivax is a priority.  
Methods 
A high-throughput LAMP assay targeting a P. vivax mitochondrial gene and deploying 
colorimetric detection in a 96-well plate format was developed and evaluated in the 
laboratory. Diagnostic accuracy was compared against microscopy, antigen detection tests 
and PCR and validated in samples from malaria patients and community controls in a district 
hospital setting in Sabah, Malaysia. 
Results 
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The high throughput LAMP-P. vivax assay (HtLAMP-Pv) performed with an estimated limit of 
detection of 1.4 parasites/ µL. Assay primers demonstrated cross-reactivity with P. knowlesi 
but not with other Plasmodium spp. Field testing of HtLAMP-Pv was conducted using 149 
samples from symptomatic malaria patients (64 P. vivax, 17 P. falciparum, 56 P. knowlesi, 7 
P. malariae, 1 mixed P. knowlesi/P. vivax, with 4 excluded).  When compared against 
multiplex PCR, HtLAMP-Pv demonstrated a sensitivity for P. vivax of 95% (95% CI 87-99%); 
61/64), and specificity of 100% (95% CI 86 – 100%); 25/25) when P. knowlesi samples were 
excluded. HtLAMP-Pv testing of 112 samples from asymptomatic community controls, 7 of 
which had submicroscopic P. vivax infections by PCR, showed a sensitivity of 71% (95% CI 
29-96%; 5/7) and specificity of 93% (95% CI87-97%; 98/105).  
Conclusion 
This novel HtLAMP-P. vivax assay has the potential to be a useful field applicable molecular 
diagnostic test for P. vivax infection in elimination settings.  
 
Author Summary 
Plasmodium vivax has a worldwide distribution and is the second most common causative 
agent of human malaria. The dormant liver stage of P. vivax allows the infection to recur 
unless diagnosed and treated appropriately, which poses a significant challenge to the goals 
of malaria elimination and eradication as outlined by the WHO. Although highly sensitive 
molecular diagnostic tools are available in reference laboratory settings, the currently 
available diagnostic tools outside referral settings for the detection of P. vivax are limited to 
microscopy and rapid diagnostic tests, which are insufficiently sensitive for the detection of 
low level parasitemia particularly in asymptomatic individuals. Based on a DNA amplification 
technology called loop-mediated isothermal amplification (LAMP), this study describes the 
development and validation of a colourimetric, high throughput assay (HtLAMP) suitable for 
the detection of P. vivax infection in non-referral settings. The sensitivity of the assay 
combined with its field applicability offers the potential for it to play an important role as a 
diagnostic tool for the purpose of malaria elimination. 
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Background 
Plasmodium vivax is the most geographically widespread of the Plasmodium species that 
infect humans [1] and can cause severe and fatal disease [2].   In the 2014 World Malaria 
Report it was estimated that there were 15.8 million cases of P. vivax in 2013, accounting for 
47% of malaria cases outside the African region [3].  Asymptomatic sub-microscopic P. vivax 
infection is commonly reported in endemic countries [4-6], accounting for on average 69.5% 
of P. vivax infection relative to those with patent parasitaemias from community surveys [7], 
compared with 50.8% for P. falciparum  [8].  The parasite reservoir of P. vivax is also aided by 
the dormant liver stage which can cause relapsing infection, with fast gametocyte production 
allowing transmission earlier in the course of the disease, and the development of multidrug 
resistance [9]  posing difficulties for both clinical management and malaria elimination goals.  
In non-referral settings in elimination areas, the diagnostic tools currently available for 
detection of P. vivax infections for case management and surveillance are microscopy and 
immunochromatographic lateral-flow antigen detection in the form of “rapid diagnostic tests” 
(RDTs). Reference laboratories may also offer expert microscopy and PCR. The reliability of 
RDTs for diagnosing P. vivax infections, particularly at low level parasitemia, remains less 
than that for P. falciparum [4, 10]. While the most recent WHO RDT testing report found the 
highest performing parasite lactate-dehyrogenase (pLDH) based P. vivax RDTs were 
equivalent to HRP2-based P. falciparum RDTs at parasitemias of 200/µL [11], they remain 
inadequately sensitive for the detection of lower level P. vivax and P. falciparum parasitemia 
in sub-patent asymptomatic individuals. While microscopy and RDT provide adequate 
diagnostic accuracy for case management of symptomatic patients in clinical settings, they 
have been shown to be inadequate in detecting a large proportion of low density P.falciparum 
infections in active community surveillance [12], and for mass screening and treatment 
programs [13]. Studies using RDTs specifically for detection of P. vivax in this context are yet 
to be performed, although similar results could be expected given the inherently lower 
parasitemias associated with P. vivax infection.  Although molecular based assays such as 
conventional PCR are capable of detecting very low density infections, they are not suitable 
for large scale community surveillance due to complex procedures that do not allow provision 
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of test results on the day of sample, expensive reagents and the requirement for specialised 
equipment.  
Loop mediated isothermal amplification (LAMP) is a molecular diagnostic technology that has 
the potential to be a readily-applicable tool in settings such as malaria elimination. LAMP is an 
isothermal process that relies on the Bacillus stearothermophilus (Bst) enzyme and does not 
require cyclical temperature changes [14]. As such, unlike PCR, it offers an opportunity for 
field adaptation because of its low technology requirement. The output of a LAMP reaction 
can be visualised as a magnesium pyrophosphate precipitate detectable by turbidimetry [14], 
metal ion detectors such as calcein [15], hydroxynaphthol blue [16] and pico-green [17]. In 
addition to melting curve analysis [18], LAMP end products have also been visualised using a 
bioluminescent output in real time (BART) [19], a lateral flow dipstick [20], or a portable device 
with a fluorescence detecting unit (realAmp) [21].  LAMP has also recently been performed on 
non-instrumented nucleic acid amplification (NINA) platforms [22] improving its potential for 
field application.    
LAMP has been shown to detect all Plasmodium species [23] including P. knowlesi [24, 25], 
to be amenable to use with crudely extracted DNA from whole blood [26], and to have a limit 
of detection of 5 parasites/ µL for identifying Plasmodium genus and P. falciparum [27]. 
Commercially available Loopamp MALARIA detection kits (Eiken chemical co) using 
Plasmodium genus and P. falciparum have been found to perform well in regional health 
facilities, but were not capable of specifically detecting P. vivax [28, 29] . Furthermore, for 
specific detection of P. vivax, the three LAMP assays published to date have had low analytic 
sensitivity, with reported detection limits of 100 plasmid copies/ µL for 18s rRNA target [23]( 
which was equivalent to 500 parasites/ µL when tested by Patel et.al [30]), 125 parasites/µL 
for Pvr64 target (highly conserved repeat region in P. vivax genome) [30] and 100 copies/ µL 
for alpha-tubulin target [31].   
Here we describe the development and validation of a novel P. vivax specific LAMP assay 
targeting mitochondrial DNA in a high-throughput, colourimetric platform. Its performance was 
compared to PCR and microscopy in a district hospital, non reference laboratory setting. 
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Methods 
The clinical samples used retrospectively in this study to validate the P. vivax specific primers 
were obtained with ethics approval granted by the Malaysian Medical Research Ethics 
Committee, Menzies School of Health Research, Australia, and London School of Hygiene 
and Tropical Medicine, UK. 
Parasite samples used for validating primers and limit of detection (LOD) 
Primers were tested against parasite DNA from well characterised parasite lines and clinical 
samples of P. falciparum (3D7), P. vivax, P. malariae, P. ovale spp. and P. knowlesi for cross-
reactivity and LOD.   
In order to determine the analytical sensitivity of the HtLAMP-Pv, a two-fold dilution series of a 
P. vivax DNA sample beginning at a starting parasitemia of 90,000 parasites/ µL (as 
determined by quantitative PCR) was evaluated in duplicate. HtLAMP-Pv performance was 
compared with that of previously published P. vivax primers [23, 30] in the HtLAMP platform. 
In addition, a sample of starting parasitemia of 2000 parasites/ µL (as determined by expert 
microscopy) was serially diluted in 50% haematocrit uninfected blood. DNA from each dilution 
was extracted using Qiagen blood kit and tested in duplicate using the HtLAMP-Pv assay. 
Comparison between HtLAMP-Pv and RDT 
The limit of detection of the HtLAMP-Pv assay was compared with the SD Bioline Pf/Pan RDT 
(Alere Standard Diagnostics). This RDT detects P. falciparum histidine-rich protein II (HRP-II) 
and Plasmodium lactate dehydrogenase (pLDH) with a reported sensitivity of 100% at 200 
parasites/µL [11], microscopy and quantitative PCR on a blood sample obtained from a P. 
vivax blood stage clinical trial (ACTRN12614000930684) participant. Informed consent was 
obtained as per the approval of the QIMR Berghofer HREC. Briefly, a wild type P. vivax bank 
was produced using blood collected from a patient, who had returned to Australia from a 
malaria endemic country with PCR-proven P. vivax malaria infection, prior to treatment with 
artemether-lumefantrine. The clinical trial was performed as described [32] and a 2 ml EDTA-
blood sample was collected from the clinical trial participant at peak parasitemia prior to 
commencement of antimalarial treatment. This sample was serially diluted in 50% 
haematocrit blood and each dilution was subjected to an LDH ELISA assay, thick film blood 
95 
 
smear for expert microscopy, an SD Bioline Pf/Pan RDT (Alere Standard Diagnostics) and 4 x 
5 µL filter paper (whatman) blood spots. The filter paper blood spots and the remaining whole 
blood, which had been stored at -20°C, was extracted in 10 µL and 50 µL volumes using 
modified chelex-saponin based DNA extraction protocols as described below. The extracted 
DNA was stored at -20°C until performance of the HtLAMP-Pv assay. 
Diagnostic accuracy and field testing of HtLAMP-Pv 
The sensitivity and specificity of the P. vivax HtLAMP was tested retrospectively on clinical 
samples from patients enrolled in a randomised controlled trial and case-control study 
performed in Sabah, Malaysia commencing in December 2012 as outlined by Grigg et al. [33]. 
Briefly, samples were collected from microscopy positive, symptomatic patients presenting as 
outpatients  to Kota Marudu District Hospital and asymptomatic, microscopy negative, 
community controls as a result of reactive active case detection from within the village of a 
case patient from Kota Marudu district, Sabah. These were stored as 20 µL filter paper 
(Whatman) blood spots. A subset of 149 microscopy positive samples and 112 microscopy 
negative samples were used to compare the performance of the P. vivax HtLAMP (HtLAMP-
Pv), with microscopy and PCR. DNA extraction of the filter paper samples from symptomatic 
patients and HtLAMP-Pv were performed in the Kota Marudu district hospital laboratory, with 
no standing molecular diagnostic capability, using a plastic bucket adapted into a water bath, 
a centrifuge and a portable spectrophotometer. Two local staff members were trained in the 
process of performing and interpreting the assay as part of its evaluation. 
DNA extraction 
The P.vivax DNA used for the analysis of sensitivity was extracted from whole blood samples 
as per Qiagen manufacturing protocol (QIAamp DNA mini kit) with some modifications.  
Briefly, 500 µL of packed red cell blood sample was mixed with 500 µL of PBS. To an aliquot 
of 500 µL of this mix, 400 µL of Qiagen AL Lysis buffer and 40 µL of Qiagen proteinase K 
were added. After incubation at 56°C for 10 minutes, 400 µL of 100% ethanol was added, 
mixed then loaded into a spin column for centrifugation at 8,000 rpm for 1 min. The spin 
column was then washed once with 650 µL of AW1 and then AW2 spinning each wash at 
8,000 rpm for 1 min followed by a dry spin after the AW2 wash at 13,000 rpm for 1 minute. 
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Nucleic acid extract were eluted in 100 µL of elution buffer and stored at -20°C until LAMP 
reactions were performed. 
P. vivax DNA from the Kota Marudu clinical filter spot samples from symptomatic patients was 
extracted using an established chelex protocol [34] with incubations shortened to improve 
turnaround time. Briefly, 6 mm filter paper punch samples were incubated in PBS containing 
0.5% saponin for 2 hours at 37°C, before being centrifuged, washed in PBS, heated at 98°C 
for 30 minutes in 150 µL 6% chelex and centrifuged at 4,000 rpm for 3 minutes. The resultant 
100 µL DNA supernatant was then stored at -20°C until analysis by PCR and LAMP.  
Red cell pellet samples from asymptomatic individuals were extracted using a different chelex 
protocol. Briefly, 1 ml of non-ionised water was incubated with 10 µL of whole blood for 15- 30 
minutes at room temperature, followed by centrifugation at 10,000-15,000 x g for 3 minutes. 
After discarding supernatant, 200 µL of 5% chelex was added, vortexed for 5-10 seconds, 
incubated at 55°C for 30- 90 minutes and vortexed again for 5-10 seconds. The sample was 
then heated for 10 minutes at 100°C, vortexed for 5-10 seconds and centrifuged for 3 minutes 
at 10,000-15,000 x g. The DNA supernatant was placed in a sterile microfuge tube for storage 
at -20°C.   
Whole blood samples, for the comparative study with RDTs, were extracted using a chelex-
based DNA extraction methodology [35] modified by the addition of saponin.  Briefly, 10 µL of 
whole blood was mixed with either 200 µL of 0.5% saponin and incubated at 37°C for 30 
minutes. Samples were then centrifuged, supernatant discarded and pellet heated at 98°C in 
150 µL of 6% chelex for 30 minutes. The resultant supernatant was stored at -20°C. The 
process was also performed on 50 µL of whole blood. 
Positive control plasmid 
In order to establish specificity of the P. vivax LAMP primers, a plasmid containing P. vivax 
cox1 gene was constructed. The target region of the gene was amplified using COX1 specific 
PCR primers. Reactions were performed in 20 µL total volume containing 1X NH4 buffer, 2 
mM MgCl2, 200 µM dNTPs, 200 µM primer mix and 0.5 U Taq polymerase (Bioline). The 
~500 bp PCR product was visualised following agarose gel electrophoresis. The PCR product 
was purified using a commercial kit (Roche) and TA cloned using pGEM-T easy as per 
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manufacturer instructions. Recombinant E. coli were identified by blue-white colour selection. 
Presence of the P. vivax cox1 gene within the plasmid was confirmed by PCR and Sanger 
sequencing. 
Estimation of the number of mitochondrial cox1 genes in the P. vivax genome 
Copy number of the pvcox1 gene in the P. vivax genome was estimated by quantitative real 
time PCR SYBR green PCR assay using the Light Cycler 96 (Roche). Two single copy genes 
coding for P. vivax mdr1 (GenBank  Acc No. AY618622.1) and P. vivax aldolase (GenBank 
Acc No. AF247063) were used as reference genes to estimate the pvcox1 copy number.  
PCR reactions were set up in triplicates using the Roche Fast Start Essential DNA Green 
Master Mix (Cat. No. 06 402 712 001), 10 µM of each primer (Table 1) and 1 µl of each DNA 
(cox1 plasmid, mdr/aldolase plasmid, Pv gDNA) in a 12 µl reaction volume. Cycling conditions 
were: 950 C for 3 mins; 45 cycles of 950 C 30 secs and 600 C for 1 min. This was followed by 
melt curve analysis to confirm correct products were synthesised.  
Table 4:1 Primers used to amplify Plasmodium vivax mdr, aldolase and cox 1  
(*Source Suwanarusk, 2007 [36]) 
Gene Primer name Sequence 
pv mdr* Pvmdr F 
Pvmdr R 
5’ CTGATACAAGTGAGG AAG AACTAC G 3’ 
5’ GTCCACCTGACAACTTAGATGC 3’  
pv aldolase* Pvaldo F 
PvaldoR 
5’ GACAGTGCCACCATCCTTACC 3’ 
5’ CCTTCTCAACATTCTCCTTCTTTCC 3’  
pv cox 1 V1V2F3 
V1V2B3 
5’ GGTACTGGATGGACTTTATAT 3’ 
5’ GGTAATGTTAATAATAGCATTACAG 3’ 
   
To assess PCR amplification efficiencies, standard curves containing five ten-fold dilutions of 
two plasmids containing either pvcox 1, or pvmdr1 and pvaldolase (1:1) Suwanarusk , 2007 
[36] were prepared, starting from the same initial concentration of 7.2 x10-4  ng/µl . Differences 
in CT value between pvcox1 and pvmdr1/pvaldolase at each plasmid concentration was 
calculated and averaged to derive ΔCTcal.  After confirming similar amplification efficiencies, 
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genomic DNA extracted from 5 well characterised P. vivax isolates with varying DNA 
concentrations were used in the copy number assay. These samples were from patients 
enrolled in a clinical trial and surveillance study, with ethics approval granted by the 
Malaysian Medical Research Ethics Committee and Menzies School of Health Research, 
Australia, conducted in Kota Marudu district, Sabah, Malaysia [37, 38].  Mean Ct values were 
calculated from triplicate and analysed using Graph Pad Prism (version 6).  The pvcox1 copy 
number in each sample was calculated as N = 2 ΔΔ Ct +/- SD  i.e. N = 2 (CTpvmdr1-CTpvcox1)-
(CTpvmdr1cal-CTpvcox1cal) as reported in Suwanarusk, 2007 [36].  
PCR 
Nested PCR for P. vivax was performed as previously published [39]. Reactions were 
performed in 20 µL total volume containing 1X buffer, 2 mM MgCl2, 200 µM dNTPs, 200 µM 
primer mix (rPLU5new/rPLU6 for nest 1 and rVIV1/rVIV2 for nest 2) and 0.5 U Taq 
polymerase (Bioline). PCR products were visualised on a 2% agarose gel. 
Multiplex PCR [40] for the detection of P. falciparum, P. vivax, P. malariae and P. ovale was 
performed on clinical samples from the 149 symptomatic case samples, with P. knowlesi 
confirmed using PCR as described by Imwong et al. [41]. Nested PCR, as described by Singh 
et al. [42], was performed on the 112 community control samples. Quantitative PCR on the P. 
vivax blood stage clinical trial sample was performed as previously described [32]. 
High-throughput LAMP  
High throughput (HtLAMP) was performed on a 96-well standard u-bottom microtitre plate 
(Sterihealth) as previously described [43]. Briefly, reactions were performed in 25 µL total 
volume containing 5 µL DNA, 1X buffer (20 mM Tris HCL pH 8.8, 10 mM KCl, 8 mM MgSO4, 
10 mM(NH4)SO4), 1.25 mM each dNTP, 1.78 µM each FIP/ BIP, 0.8 µM each LF/ LB, 0.2 µM 
each F3/ B3), 120 µM hydroxynaphthol-blue (Fluka, CAS number 63451-35-4)and 8 units Bst 
polymerase (New England Biolabs, Ipswich, MA). The microtitre plate was incubated in a 
waterbath at 65°C for 30 minutes before the colour change and precipitate in each well was 
recorded. A blue colour change with a visible precipitate was scored as a positive result, and 
purple colour without a precipitate was a negative result (Figure 4.1). The microtitre plate was 
then read in an ELISA plate reader at 600 nm wavelength to obtain an optical density (OD) 
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reading of each well. The threshold value for a positive reaction was calculated using the 
mean plus two standard deviations of the no template control (NTC) wells. A positive or 
negative OD reading for each sample was then calculated using the threshold value and 
correlated with the visually detected colour change. Samples that were discordant in terms of 
colour change and OD threshold were deemed negative.  
Figure 4:1 HtLAMP colour change associated with hydroxynaphtholblue (HNB) 
Left clear, purple colour = negative and right cloudy, blue colour = positive 
 
 
Statistical analysis 
PCR, nested or multiplex, for the detection of P. vivax was used as the gold standard by 
which the sensitivity and specificity of HtLAMP-Pv was calculated. PCR is the best 
established molecular diagnostic tool available for the detection of Plasmodium parasites and 
therefore an appropriate choice for comparison of a new molecular diagnostic modality. 
Sensitivity was estimated as the number of LAMP positives that were also PCR positive, 
divided by the number of PCR positives.  Specificity was estimated as the number of LAMP 
negatives that were also PCR negative divided by the total number of PCR negatives.    
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Results 
P.vivax LAMP primers 
Two sets of LAMP primers (VIV1 and VIV2) targeting P. vivax mitochondrial sequences were 
designed manually. Each set of primers was tested for its ability to amplify P. vivax-specific 
DNA. However, only one set of primers (VIV2) targeting the P. vivax mitochondrial cox1 gene 
(Table 4.2 and Figure 4.2), was subject to further validation as the other set failed to amplify 
P. vivax DNA. The specificity of VIV2 primers was investigated by searching for nucleotide 
similarity using the BLAST algorithm at the NCBI nucleotide database 
(www.ncbi.nlm.nih.gov/Blast.cgi ) and found to have limited sequence identity only to other 
Plasmodium species. Given the conserved nature of the mitochondrial genome and the 
sequence similarity across different P.vivax strains from around the world, no evaluation of 
VIV2 primers on different P.vivax strains was performed.  
 
Table 4:2  P. vivax VIV2 HtLAMP primer sequences (5’  3’) 
Primer Sequence 
F3 GGTACTGGATGGACTTTATAT 
B3 GGTAATGTTAATAATAGCATTACAG 
LF GATAACATCTACTGCAACAGG 
LB CTACTGTAATGCATCTAAGATC 
FIP CCAGATACTAAAAGACCAACCCACCATTAAGTACATCACT 
BIP GCTAGTATTATGTCTTCTTTCACTTAATATACCAAGTGTTAAACC 
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Figure 4:2  P. vivax VIV2 HtLAMP primer set superimposed on alignments of P. vivax 
(AY598035), P. falciparum (AJ276844) and P. knowlesi ( NC_007232)  cox1 genes 
 
 
Species-specificity of VIV2 LAMP primers 
The VIV2 primer set was tested in duplicate on DNA extracts from one PCR-confirmed 
sample of each of the following species:  P. vivax, P. falciparum, P. knowlesi, P. malariae, P. 
ovale wallikeri and P. ovale curtisi. There was amplification of P. vivax and P. knowlesi DNA 
but no amplification product was detected for P. falciparum, P. malariae, P. ovale wallikeri or 
P. ovale curtisi .   
Quantification of mitochondrial cox1 gene copy numbers in the P. vivax genome 
Using the single-copy P. vivax aldolase gene as reference, the estimated copy number of 
pvcox1 in five selected P. vivax samples ranged from 9.2 – 16.47 with a mean of 12.43( ± 
1.233 ). Using the pvmdr1 gene as reference, the estimated copy number of pvcox1 ranged 
from 7.32 – 14.05 with a mean of 10.28 (± 1.182) (Figure 4.3). 
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Figure 4:3  Estimated Plasmodium vivax cox1 copy number based on comparison with two 
single copy genes, pv aldolase1 and pvmdr1  
 
 
 
Limit of detection of HtLAMP-Pv  
Using a two-fold DNA dilution series of a clinical P. vivax sample, with a starting parasitemia 
of 90,000 parasites/ µL as determined by quantitative PCR, the LOD was 1.4 parasites/ µL 
(Table 4.3). Using the same dilutions, the LOD of P. vivax LAMP primers published by Han 
[23] and Patel [30], in the HtLAMP platform was determined to be706 parasites/ µL and 176 
parasites/ µL respectively. HtLAMP-Pv performed on the microscopy-determined P. vivax 
dilution series in whole blood had an LOD of 2 parasites/ µL (Table 4.4). 
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Table 4:3  Analytical sensitivity of HtLAMP-Pv, compared with other published P. vivax LAMP 
primers, using a DNA dilution series of clinical sample with qPCR confirmed parasitemia  
 
Each sample was tested in duplicate in the HtLAMP platform using each of the three P. vivax 
LAMP primer sets. The dilution at which both duplicates were positive was the limit of 
detection for each of the primer sets in the HtLAMP platform (Pos* indicates dilutions at which 
only one of the duplicates was positive). HtLAMP-Pv was able to detect 1.4 parasites/ µL 
compared with previously published P. vivax LAMP primers. 
 
 
Sample Quantitative PCR  
(parasites/µL calculated) 
Han et al. 
18s rRNA 
target 
 
Patel et al. 
Pvr64 
target 
HtLAMP-Pv  
cox1 target  
1 
Original 
90,000 Pos  Pos  Pos  
2 45,000 Pos  Pos  Pos  
3 22,500 Pos  Pos  Pos  
4 11,250 Pos  Pos  Pos  
5 5625 Pos  Pos  Pos  
6 2813 Pos  Pos  Pos  
7 1406 Pos  Pos  Pos  
8 703 Pos  Pos Pos 
9 352 Pos* Pos Pos 
10 176  Pos Pos 
11 88   Pos 
12 44   Pos 
13 22   Pos 
14 11   Pos 
15 5.5   Pos 
16 2.7  Pos* Pos 
17 1.4   Pos 
18 0.7   Pos* 
19 0.3    
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Table 4:4  Analytical sensitivity of HtLAMP-Pv on microscopy-determined whole blood P. 
vivax dilution series 
 
The limit of detection HtLAMP-Pv is 2 parasites/ µL, performed in duplicate and where both 
duplicates were positive. 
 
 
P. vivax 
Parasites /µL 
HtLAMP-Pv 
2000 Pos 
200 Pos 
20 Pos 
2 Pos 
0.2 Neg 
0 Neg 
 
HtLAMP-Pv vs RDT  
Quantitative PCR analysis of the P. vivax blood stage clinical trial sample confirmed a peak 
parasitemia of 12 parasites/ µL prior to commencement of antimalarial therapy. HtLAMP-Pv 
was positive and the RDT was negative at this level of parasitemia. The limit of detection 
(LOD) of the HtLAMP-Pv assay varied depending on the type and volume of sample from 
which DNA was extracted. The LOD for filter paper extracted using saponin and chelex was 
more than 12 parasites/ µL whereas the LOD for 10 µL and 50 µL of whole blood extracted 
using saponin and chelex was 3 parasites/ µL and 1.5 parasites/ µL respectively (Table 4.5). 
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Table 4:5 Comparing microscopy and RDT with the limit of detection of HtLAMP-Pv using 
filter paper and whole blood at 10 µL and 50 µL volumes 
The limit of detection (LOD) of the HtLAMP-Pv assay depends on the starting sample material 
and the volume of blood extracted. LOD threshold was determined by the presence of 2 
positive duplicate tests (ie: 4 positive results) at a particular parasitemia. The LOD for a 5 µL 
filter paper blood spot extracted using a chelex-saponin protocol was more than 12 parasites/ 
µL. The LOD for 10 µL of whole blood extracted using a chelex-saponin protocol was 3 
parasites/ µL compared with 50 µL of whole blood which was 1.5 parasites/ µL. 
 
 0.75  
parasites/ µL 
 
1.5 
parasites/ µL 
 
3.0 
parasites/ µL 
 
6.0 
parasites/ µL 
 
12 
parasites/ µL 
 
Microscopy Neg Neg Pos Pos Pos  
RDT Neg Neg Neg Neg Neg 
Filter paper (5 µL) Neg Neg Neg Neg Pos 
Whole blood 10 µL Neg Neg Pos Pos Pos 
Whole blood 50 µL Neg Pos  Pos Pos Pos 
 
 
Sensitivity and specificity of HtLAMP-Pv in symptomatic patients 
Of the 149 patients with microscopy-confirmed malaria from the district of Kota Marudu, 
Sabah, Malaysia, 145 were confirmed by PCR: 4 samples were excluded due to lack of 
microscopy and PCR data, 56 were identified as P. knowlesi (median parasitemia 2005 
parasites/ µL, range 26- 143,790), 64 as P. vivax (median parasitemia 4676 parasites/ µL, 
range 53- 89,640), 7 as P. malariae, 17 as P. falciparum (median parasitemia  18,725 
parasites/ µL, range 837- 693,922) and 1 as a mixed P knowlesi/P. vivax infection. HtLAMP-
Pv was compared with multiplex PCR in these clinical samples. The sensitivity of HtLAMP-Pv 
for P. vivax was 95% (62/65, 95% CI 87-99) and specificity was 55% (44/80, 95% CI 43-66) 
respectively compared with multiplex PCR and 94% (59/62, 95% CI 85-98) and 53% (44/83, 
95% CI 42-64) respectively compared with expert microscopy (Table 2). The low specificity of 
the assay can be attributed to cross-reactivity of the VIV2 primers with P. knowlesi, with 97% 
sequence homology at the cox1 gene between P. vivax and P. knowlesi. When P. knowlesi 
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samples were excluded from the analysis, the specificity was 100% compared with both 
multiplex PCR and microscopy (Table 4.6).  
Table 4:6 Sensitivity and Specificity of HtLAMP-Pv for P. vivax in symptomatic patients in 
Sabah with P. falciparum, P. vivax and P. knowlesi 
149 filter paper samples were tested by HtLAMP-Pv; 4 samples were excluded due to a lack 
of PCR and microscopy data. Among the 145 samples, PCR confirmation of species was as 
follows: n =64 P. vivax n = 56 P. knowlesi, n= 17 P. falciparum, n= 7 P. malariae and n= 1 
mixed P. vivax/P. knowlesi infection  
 
 Sensitivity Specificity 
HtLAMP-Pv compared with multiplex 
PCR 
62/65(95%)       
(95% CI 87-99) 
44/80 (55%)       
(95% CI 43-66) 
HtLAMP-Pv compared with multiplex 
PCR excluding Pk samples 
62/65(95%)       
(95% CI 87-99) 
24/24 (100%)       
(95% CI 87-99) 
HtLAMP-Pv compared with  microscopy 59/62 (95%)       
(95% CI 85-98) 
44/83 (53%)       
(95% CI 42-64) 
HtLAMP-Pv compared with microscopy 
excluding Pk samples 
59/62 (95%)       
(95% CI 85-98) 
18/18 (100%)       
(95% CI 81-100) 
Multiplex PCR compared with 
microscopy 
60/65 (92%)       
(95% CI 83-97) 
78/80 (98%)       
(95% CI 91-99) 
 
Sensitivity and specificity of HtLAMP-Pv in asymptomatic, reactive active case detection 
community control patients 
HtLAMP-Pv was compared with nested PCR for red cell pellet samples from asymptomatic, 
microscopy negative community controls from the malaria endemic district of Kota Marudu, 
Sabah, Malaysia. The sensitivity of HtLAMP-Pv was 71% (95% CI 29-96; 5/7) and specificity 
was 93% (95% CI 87-97; 98/105) compared with PCR.  
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Turnaround time of assay 
The HtLAMP assay turnaround time was 1 hour after DNA extraction, 4 hours when combined 
with whole blood chelex saponin protocol and 6 hours when combined with filter paper rapid 
DNA extraction protocol. 
Applicability of the assay in a non-reference laboratory in a resource limited setting 
HtLAMP-Pv testing of a total of 149 filter paper samples was performed successfully in a 
regional hospital laboratory in Kota Marudu district, Sabah, Malaysia. Good workflow set up 
ensured that there was no contamination despite the lack of formal molecular diagnostic 
infrastructure. Locally trained staff was able to perform and interpret results of the HtLAMP-Pv 
assay using only a centrifuge, pipettes, water bath and a portable spectrophotometer. 
 
Discussion 
Field-applicable diagnostic tools for the detection of Plasmodium vivax are essential 
components for the malaria eradication agenda [44]. Given the widespread distribution and 
unique challenges P. vivax poses compared with P. falciparum, there is a pressing need for 
the development of species- specific molecular diagnostic tools. LAMP is a molecular 
diagnostic tool which holds much promise in terms of its ability to be deployed in non-referral 
laboratory settings, given its simplicity and rapid assay turnaround time, ability to be 
performed on crudely extracted DNA from both whole blood and filter paper and lack of 
expensive equipment. The colourimetric 96 well microtitre plate-based platform for performing 
LAMP (HtLAMP) for the detection of Plasmodium parasites, as previously described [43], 
increases the throughput of the LAMP, using minimal equipment. The objective of this paper 
was to develop and validate a P. vivax specific HtLAMP assay on this platform with good 
diagnostic accuracy. 
The 6-kb mitochondrial genome of the genus Plasmodium encodes three mitochondrial 
proteins- cytochrome B (cytb) and subunit 1 and 3 of cytochrome c oxidase (cox1 and cox3), 
and is estimated to be present in relatively high copy number. The complete mitochondrial 
genome of P. vivax (Genbank AY598035) has been shown to be closely related to P. 
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knowlesi [45]. Previously published standard PCR primers for P. vivax targeting cox1 have 
shown 100% sensitivity and specificity [46], but were not evaluated against P. knowlesi. 
LAMP primers targeting mitochondrial sequences for the detection of P. genus and P. 
falciparum demonstrated an analytical sensitivity of 5 parasites/ µL [27] suggesting that 
mitochondrial DNA offers an attractive target, presumably due to increased copy number of 
mitochondrial targets within cells. Recent estimates of genomic sequence coverage have 
shown that the P. falciparum genome contains ~20 copies/cell of the mitochondrial genome 
[47]. 
This HtLAMP-Pv assay targeting the conserved cox1 gene demonstrated excellent analytic 
sensitivity, being able to detect 1.4 parasites/ µL. This is the lowest LOD so far achieved for a 
published P. vivax –specific LAMP assay. The estimated copy number for cox1 in P. vivax is 
approximately 11 copies/ cell. Therefore, it is likely that the sensitivity of the HtLAMP-Pv 
assay is a reflection of the increased number of mitochondrial targets per cell. Previously 
published P. vivax LAMP primers, which targeted non-mitochondrial genes, when used in the 
HtLAMP platform had limits of detection of 706 parasites/ µL and 176 parasites/ µL which 
correlated well with published limits of detection of 125-500 parasites/ µL for these P. vivax 
primers sets [30].  
The pkcox1 gene of P. knowlesi exhibits 97% sequence identity with pvcox1 at the nucleotide 
level, and thus the cross-reactivity of the VIV2 primers between these two species was 
expected. However, there was no cross-reactivity with P. falciparum (87% sequence identity), 
P. ovale wallikeri (92%), P. ovale curtisi (92%) or P. malariae (93%).  
Validation of the HtLAMP-Pv in clinical samples of symptomatic patients with vivax, 
falciparum and knowlesi malaria demonstrated sensitivity for P. vivax of 94-95% and a 
specificity of 53-55% compared with microscopy and multiplex PCR respectively. The poor 
specificity however was a reflection of the cross-reactivity with P. knowlesi. When P. knowlesi 
samples were excluded from the analysis, the specificity of the HtLAMP-Pv assay improved to 
100%, compared with both multiplex PCR and microscopy.  
While this cross-reactivity appears to be a limitation of this HtLAMP-Pv assay, P. knowlesi 
malaria is uncommon or absent in most areas of P. vivax endemicity, so this would be an 
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important consideration only in Malaysia, where P. knowlesi predominates [48] and in the 
other countries in south-east Asia where P. knowlesi human infection has been documented 
[49]. In terms of treatment, both P. vivax and P. knowlesi respond to artemisinin-based 
combination therapy (ACT) [50]. However, in elimination programmes utilising primaquine for 
radical cure of P. vivax malaria, there is a potential risk of inappropriate use of this potentially 
haemolytic drug in people with P. knowlesi infections. This is a problem localised to Southeast 
Asia, and would not pose a problem for LAMP-based detection and radical treatment of P. 
vivax for malaria elimination elsewhere.   
The HtLAMP-Pv assay was also evaluated in a limited sample set of asymptomatic, 
microscopy negative, community control patients enrolled from the same village as a case 
patient, as a result of reactive active case detection. Although the LOD of HtLAMP-Pv 
appears to be 1.4 parasites/ µL, in this sample set its sensitivity was only 71%. This may be 
due to the very low parasitemias in these 7 PCR positive samples or variability due to 
stochastic effects at such low parasitemias. Therefore further validation in a larger sample set 
is required to confirm the sensitivity of HtLAMP-Pv in this population in order to evaluate the 
potential role for HtLAMP-Pv as a diagnostic tool in malaria elimination settings.  
HtLAMP-Pv showed significantly better sensitivity than the SD Bioline Pf/Pan RDT at low 
parasitemia. RDTs were negative in the serially diluted samples at 12 parasites/ µL. HtLAMP-
Pv was positive at this level. The analytical sensitivity of the assay varied depending on 
whether filter paper samples or whole blood was used irrespective of the chelex-saponin DNA 
extraction protocol used. This may have important implications for choosing the type of 
sample collected in addition to choosing the appropriate diagnostic tool for surveillance or 
screening policy and protocols for malaria elimination programs.  
In this study we also demonstrated that HtLAMP-Pv performed well in the 96-well microtitre 
plate platform for increasing the throughput of the assay in a non-referral laboratory in a 
district hospital in Sabah, Malaysia. DNA extraction was performed in the non-referral 
laboratory using a chelex protocol on filter paper blood spots and the HtLAMP-Pv assay was 
able to process these samples in a simple water-bath within one hour from time of DNA 
extraction. Positive and negative results were readily identified by two locally trained staff by 
visual inspection of the colour change. Optical densitometry readings at 600 nm in portable 
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photospectrometer were used to provide objective confirmation of the visually detected 
results. As such the validation of this HtLAMP-Pv assay in a rural district laboratory setting 
confirms the potential it has as a field-applicable molecular diagnostic tool. Furthermore,  the 
process of assay validation using the combination of visual and optical densitometry values 
has previously shown that the visually detectable colour change was reliable for determining 
both positive and negative results [43]. Therefore while the photospectrometer offers objective 
confirmation, it is not an essential component of the assay.  
Some of the limitations to this platform pertain to DNA extraction. Firstly, in order to maintain 
cost effectiveness of the assay, modified chelex-based protocols were used for whole blood 
and filter paper extractions. Although these multi-step DNA extraction processes, which relied 
on a centrifuge, were performed adequately in a resource limited setting, further simplification 
of DNA extraction would enhance the feasibility of the HtLAMP-Pv assay. It would also allow 
a greater number of samples to be processed, as might be required for mass surveillance for 
malaria elimination, thereby making full use of the high throughput aspect of the HtLAMP 
platform. Secondly, while equivalent small volumes of blood on filter paper and whole blood 
have shown whole blood to produce better analytical sensitivity in the HtLAMP platform [43], 
the limit of detection of HtLAMP-Pv using larger volumes of blood on filter paper is yet to be 
established. 
In conclusion, this study outlines the development and validation of a novel P. vivax-specific 
LAMP assay which combines a low limit of detection with a high throughput, colourimetric, 
field applicable molecular diagnostic assay. As such, this HtLAMP assay holds much promise 
as a diagnostic tool to support malaria elimination efforts in resource-limited P. vivax endemic 
settings.  
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Chapter 5  
High-throughput LAMP for the identification of Plasmodium 
knowlesi 
 
P. knowlesi is difficult to diagnose but can manifest as severe clinical disease. It has a 
microscopic appearance similar to both P. falciparum and P. malariae and Plasmodium 
lactate dehydrogenase (pLDH)-based RDTs are insensitive for reliable diagnosis. Of the 
molecular diagnostic modalities, PCR is the most highly sensitive tool available for the 
detection of low level parasitemia but is generally not available in resource limited settings.  
LAMP offers an alternative molecular diagnostic option for P. knowlesi diagnosis. Currently 
there are two sets of P. knowlesi specific LAMP primers. However, these are insufficiently 
sensitive for the detection of low level parasitemia. Furthermore, they are not available in a 
diagnostic platform that is able to be performed in resource limited settings. 
Chapter Five describes the development of novel P. knowlesi LAMP primers targeting a 
mitochondrial gene. Using the HtLAMP platform described in Chapter Three, this HtLAMP-Pk 
assay has a limit of detection of 0.2 parasites/ µL. However, it has thus far only been 
validated on a small set of clinical samples from symptomatic patients, and requires further 
validation in a larger set of both symptomatic and asymptomatic patient samples. 
Nevertheless, given that the HtLAMP platform has demonstrated its field applicability, once 
validated, this HtLAMP-Pk platform has the potential to be both a sensitive point of care 
molecular diagnostic platform as well as a tool for use in cross sectional surveys in resource 
limited settings. 
Results from the development of the HtLAMP-Pk assay were accepted for publication in the 
American Journal of Tropical Medicine and Hygiene in 2016 
Britton S, Cheng Q, Grigg MJ, William T, Anstey N, McCarthy JS, Short Report: A sensitive, 
colorimetric, high throughput, Loop-mediated isothermal amplification (HtLAMP) assay for the 
detection of Plasmodium knowlesi, Am J Trop Med Hyg 2016, May 9, pii 15-0670
120 
 
Short Report: A sensitive, colorimetric, high throughput, Loop-mediated isothermal 
amplification (HtLAMP) assay for the detection of Plasmodium knowlesi  
Britton S1*, Cheng Q2, Grigg MJ3, William T4, 5, Anstey NM3, McCarthy JS1  
1 University of Queensland, Brisbane, Australia and QIMR Berghofer Medical Research Institute, Brisbane, 
Australia 
2 Australian Army Malaria Institute, Brisbane, Australia 
3 Menzies School of Health Research and Charles Darwin University, Darwin, Australia 
4 Clinical Research Centre, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia 
5Jesselton Medical Center, Kota Kinabalu, Sabah, Malaysia 
* Corresponding author 
 
 
Abstract 
The simian parasite Plasmodium knowlesi, is now the commonest cause of malaria in 
Malaysia and can rapidly cause severe and fatal malaria. However, microscopic misdiagnosis 
of Plasmodium species is common, rapid antigen detection tests remain insufficiently 
sensitive and confirmation of P. knowlesi requires PCR. Thus available point-of-care 
diagnostic tests are inadequate. This study, reports the development of a simple, sensitive 
colorimetric, high-throughput loop mediated isothermal amplification assay (HtLAMP) 
diagnostic test using novel primers for the detection of P. knowlesi. This assay is able to 
detect 0.2 parasites/ µL, and compared with PCR has a sensitivity of 96% for the detection of 
P. knowlesi, making it a potentially field-applicable point of care diagnostic tool. 
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Human infection with the simian malaria parasite, Plasmodium knowlesi results from 
transmission from long tailed and pig tailed macaques, via the Anopheles leucosphyrus 
mosquito vector [1], and has been documented in all countries of South-East Asia, except 
Laos and Timor Leste [1] In Sabah, Malaysia, while the total number of reported malaria 
cases has decreased since 1992, the absolute numbers and proportion due to P. knowlesi 
have increased significantly such that in 2013, 62% of malaria notifications were due to P. 
knowlesi, making it the most common cause of malaria in this region [2]. 
P. knowlesi malaria is difficult to diagnose by conventional microscopy. Ring and trophozoite 
stages of P. knowlesi appear morphologically very similar to both P. falciparum and P. 
malariae [1]. Microscopy has been found to be unreliable for diagnosing P. knowlesi in 
regions where it coexists with P. falciparum and P. vivax [3, 4], resulting in inappropriate or 
delayed administration of antimalarial treatment.  While high parasitemia has been found to 
predict severe disease, symptomatic disease frequently occurs at low parasitemia [5, 6]. 
There are currently no P. knowlesi-specific rapid diagnostic tests (RDTs), and those based on 
parasite lactate dehydrogenase (pLDH) and aldolase have been shown to be inadequately 
sensitive for clinical diagnosis [4, 7]. Of concern, Grigg et al. reported that for the 31% of P. 
knowlesi malaria patients with parasitemias <1000 parasites/ µL, pLDH-based RDTs had a 
sensitivity of only 12% [7]. 
Currently, definitive diagnosis of P. knowlesi infection relies on PCR performed retrospectively 
in reference laboratories. Tests that have been reported include nested PCR assays targeting 
either the 18S ribosomal small subunit [8] or the cytochrome B mitochondrial gene [9]. Assays 
have been configured as single step PCR [10], real time PCR [11], multiplex PCR [12] or 
semi-nested multiplex PCR [13]. However due to its cost and requirements for infrastructure 
and technical expertise, PCR remains a reference-laboratory confirmation tool and is 
generally inaccessible in regional healthcare facilities, making it unsuitable as a point of care 
diagnostic tool. Of the alternative molecular technologies, loop-mediated isothermal 
amplification (LAMP) offers much potential as a field applicable molecular diagnostic tool. Of 
the two published P. knowlesi -specific LAMP assays, primers targeting the beta-tubulin gene 
using a Loopamp kit (Eiken Chemical Co. Ltd, Tokyo, Japan) are yet to be validated in human 
clinical samples [14]. A LAMP assay targeting the P. knowlesi  apical membrane AMA-1 
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reported a sensitivity of 100% and specificity of 98% in 74 clinical samples [15]. However, it 
required post-amplification addition of SybR which risks contamination.  Although it has been 
recommended that LAMP be reserved for surveillance rather than point of care diagnostics, in 
view of the difficulties associated with the diagnosis of P. knowlesi using microscopy and 
RDTs, there is a pressing need for developing point of care diagnostic alternatives for the 
identification of P. knowlesi infection.  
This report describes a sensitive, high throughput, colorimetric, field-applicable LAMP assay 
targeting a mitochondrial gene that can detect P. knowlesi infection at low parasitemia.    
Novel LAMP primers (Pk101) targeting a Plasmodium mitochondrial gene (Table 5.1) were 
designed based on modification of previously designed P. vivax LAMP primers [16]. Dried 
blood spots (DBS) samples from patients with PCR-confirmed malaria caused by P. knowlesi 
(n=25; median parasitemia 1541 parasites/ µL; range 75-95 456), P. vivax (n=15; median 
parasitemia 4630 parasites/ µL; range 441-110,460), mixed P. knowlesi/P. vivax (n=1, 
parasitemia 5,767 parasites. µL), P. falciparum (n=4; median parasitemia 92,938 parasites/ 
µL; range 11,024- 362,420) and P. malariae (n=1, parasitemia 3,354 parasites/ µL) were used 
to validate the primers. These patients (n=46) were a subset of patients enrolled in 
prospective clinical studies, with ethics approval granted by the Malaysian Medical Research 
Ethics Committee and Menzies School of Health Research, Australia, conducted in Kota 
Marudu district, Sabah, Malaysia [6, 17]. Twenty µL DBS were prepared from symptomatic 
patients presenting to the district hospital with a diagnosis of malaria infection by microscopy. 
Multiplex PCR was performed as described [18] on DNA extracted using the Qiagen DNA 
mini kit (Qiagen, Australia) from clinical samples to identify Plasmodium genus and  human-
only species (P. falciparum, P. vivax, P. ovale and P. malariae), and nested PCR as 
described [8] was used for identifying P. knowlesi. HtLAMP was performed on DNA extracted 
from DBS using a modified chelex protocol l [19]. Briefly, 6 mm DBS samples were incubated 
in 1 mL of 0.5% saponin in phosphate buffered saline (PBS) for 2 hours at 37°C, centrifuged, 
washed in PBS, heated at 98°C for 30 minutes in 150 µL of 6% chelex and centrifuged at 
4,000 rpm for 3 minutes. The resultant 100 µL supernatant was stored at -20°C. 
To determine the limit of detection (LOD) of the assay, a PCR confirmed P. knowlesi sample 
with a parasitemia determined by microscopy by two expert microscopists was diluted in 
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Plasmodium negative whole blood to produce a dilution series with parasitemia ranging from 
2000, 200, 20, 2 and 0.2 parasites/ µL. The DNA from these samples was extracted using 
Qiagen© DNA mini kit (Qiagen, Australia) and tested in duplicate in the HtLAMP platform 
using Pk101 primers (HtLAMP-Pk) and published [14, 15] P. knowlesi primers (HtLAMP-Pk 
Iseki and HtLAMP-Pk Lau). HtLAMP-Pk was performed on clinical samples of P. knowlesi 
(n=8), P. falciparum (n=1), P. vivax (n=2), P. ovale (n=1) and P. malariae (n=1) in order to 
determine species specificity of the primers. HtLAMP reactions were performed in 25 µL total 
volume containing 1X buffer (20 mM Tris HCL pH 8.8, 10 mM KCl, 8 mM MgSO4, 10 
mM(NH4)SO4), 1.25 mM each dNTP, 1.78 µM each FIP/ BIP, 0.8 µM each LF/ LB, 0.2 µM 
each F3/ B3), 120 µM hydroxynaphthol-blue (Fluka, CAS number 63451-35-4, Sigma-Aldrich, 
Australia), 8 units Bst polymerase (New England Biolabs, Ipswich, MA) and 5 µL of DNA. The 
HtLAMP-Pk assay was done in a 96-well microtitre plate, incubated in a water bath at 65°C 
for 30 minutes, the resultant color change and precipitate recorded visually and confirmed 
using a portable photospectrometer at 600nm with a turnaround time of 6 hours, as previously 
described [19]. A blue color change with a visible precipitate was a positive result, and purple 
color without a precipitate was a negative result. PCR was used as the gold standard to 
calculate the sensitivity and specificity of HtLAMP-Pk. The performance of HtLAMP in a 
resource-limited setting had previously been validated in a district hospital laboratory in 
Sabah [19].  
The HtLAMP-Pk assay had a LOD of 0.2 parasites/ µL, compared with 200-2000 parasites/ 
µL for HtLAMP-Pk Iseki and 20-2000 parasites/ µL for HtLAMP-Pk Lau (Table 5.2). It is 
postulated that the HtLAMP-Pk primers are considerably more sensitive than the other 
published primers due to the high copy number of the target mitochondrial gene.  The 
HtLAMP-Pk assay did not cross-react with P. falciparum, P. malariae and P. ovale but did 
cross-react with P. vivax. However, the HtLAMP-Pk assay was more sensitive (96%, n=25/26) 
for the detection of P. knowlesi compared with a cross-reacting P. vivax HtLAMP assay [16] 
(sensitivity 42%, n = 11/26) and HtLAMP-Pk Iseki [14] (sensitivity 81%, n=21/26) (Table 5.3). 
The HtLAMP assay, validated in a district hospital laboratory in Kota Marudu, Sabah, 
Malaysia, was able to be performed in a resource limited setting with chelex- extracted DNA 
from DBS samples, using a waterbath, centrifuge and portable photospectrometer [19].  
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The main limitation of the HtLAMP-Pk assay is the cross-reactivity with P. vivax which 
resulted in a low species-specificity. Given the 97% sequence identity between these species 
at this mitochondrial target it may be challenging to further modify primer sets for this target 
site to improve species specificity. Although, artemisinin-combination therapy is effective 
treatment for both of these Plasmodium species [17], P. vivax infection would need to be 
confirmed and glucose-6-phosphate dehydrogenase deficiency excluded prior to 
administration of primaquine. Furthermore, the LOD of HtLAMP-Pk on chelex-extracted DNA 
is yet to be determined. The diagnostic sensitivity of the HtLAMP-Pk assay also requires 
further validation in a larger set of samples from both microscopy positive and negative, and 
symptomatic and asymptomatic patients with P. knowlesi malaria to establish a possible role 
for the assay as a test for detecting low level parasitemia in cross sectional surveys.  This is 
warranted due to evidence of significant asymptomatic, submicroscopic P. knowlesi carriage 
amongst household contacts of symptomatic patients [20]. In addition, although the HtLAMP 
platform performed in a resource limited laboratory setting demonstrated good diagnostic 
capability for identifying Plasmodium genus, P. falciparum [19], P. vivax [16] and P. knowlesi 
(using HtLAMP-Pk Iseki, data not shown), identification of P. knowlesi using the more 
analytically sensitive HtLAMP-Pk assay is yet to be similarly validated.   
Nevertheless, it is well recognized that P. knowlesi parasitemia can rise rapidly and cause 
severe disease. Given the diagnostic limitations of currently available tests, there is a need to 
develop more sensitive diagnostic tools to facilitate early identification of infection with this 
parasite. Although microscopy may be the mainstay of diagnosis for individual symptomatic 
patients, albeit without specificity [3], the HtLAMP-Pk assay offers a good analytical 
sensitivity, rapid turnaround time, capability of the platform to be performed in resource limited 
settings and potential for high throughput when multiple samples require testing. Therefore, 
with further refinement and validation, HtLAMP-Pk may have a potential role to play as a 
diagnostic tool for early detection of P. knowlesi in resource limited settings.  
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Table 5:1 P knowlesi Pk101 LAMP primer sequences (5’  3’) 
Abbreviation Primer sequence 
F3 GGTACTGGATGGACTTTATAT 
B3 GGTAATGTCAATAATAACATTACAG 
LF GATTACATCTACTGCAACAGG 
LB CTACTGTAATGCATTTAAGATC 
FIP CCAGACACTAAAAGACCAATCCACCATTGAGTACATCACT 
BIP GCTAGTATTATGTCTTCTTTCACTTAGTATACCAAGTGTTAAACC 
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Table 5:2 Comparative limit of detection (LOD) for 3 different P. knowlesi LAMP primers 
performed in the HtLAMP platform 
Each dilution was tested in duplicate using each of the 3 primers. ‘Positive’ grey filled values 
indicate dilutions for which both duplicates were positive by HtLAMP, ‘Positive*’ indicate 
samples with a single positive HtLAMP result and ‘Negative’ indicate samples for which both 
duplicates were negative by HtLAMP. 
P. knowlesi parasitemia 
(parasites/ µL) 
HtLAMP-Pk HtLAMP-Iseki HtLAMP-Lau 
2000 Positive Positive Positive 
200 Positive Positive* Positive* 
20 Positive Negative Positive* 
2 Positive Negative Negative 
0.2 Positive Negative Negative 
0 Negative Negative Negative 
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Table 5:3 Sensitivity and specificity of HtLAMP-Pk compared with PCR on symptomatic, 
microscopy positive, clinical dried blood spot samples 
The diagnostic accuracy of HtLAMP using 3 different LAMP primers was compared to PCR 
on DBS samples that were PCR positive for P. knowlesi (n=26) and PCR negative for P. 
knowlesi (n=20).  
 Sensitivity (n= 26) Specificity (n= 20) Specificity, excluding 
P. vivax (n= 5)  
HtLAMP-Pk 25 (96%) 95% CI 80-99 6 (30%)   95% CI 12-54 5 (100%)   95% CI 48-100 
HtLAMP-Pk Iseki 21 (81%) 95% CI 61-93 20 (100%) 95% CI 83-100  
HtLAMP-Pv 11 (42%) 95% CI 23-63 6 (30%)  95% CI 12-54  
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Chapter 6  
General Discussion and Conclusions 
 
In 2007, the WHO embarked upon the ambitious goal of malaria elimination. It is encouraging 
that, in the World Malaria Report (2014), of the 106 countries reporting ongoing transmission 
in 2000, 55 appeared to be on target to meet the Roll Back Malaria (RBM). Further, although 
the World Health Assembly target  of reducing malaria transmission by greater 75% by 2015 
represents an important target, it is worth recalling that these countries collectively accounted 
for only 6% of the total estimated cases in 2000 [1]. Nevertheless, as of December 2014, 
Azerbaijan and Sri Lanka which had ongoing transmission in 2000, reported zero locally 
acquired cases for the first time in 2013, with a further 19 countries in pre-elimination or 
elimination phases, and another 7 in prevention of malaria reintroduction phases of their 
malaria control programs [1]. 
One of the challenges facing the malaria elimination agenda is the availability of appropriate 
diagnostic tools. This is compounded by the uncertainty surrounding two major issues. Firstly, 
the minimum number of Plasmodium parasites that are able to transmit to mosquitoes in low 
transmission settings and therefore maintain the parasite lifecycle remains to be established. 
Secondly, the most effective approach to malaria elimination remains unclear: canvassed 
approaches include mass drug administration (MDA) or mass screening and treatment 
(MSAT). Answers to these two questions would facilitate the development of a target product 
profile for diagnostic tools suitable for the purpose of malaria elimination.  
In the absence of this information, the current guidelines for diagnostic tools for surveillance 
or screening in malaria elimination setting suggests 1) a minimum sensitivity and specificity of 
95%, 2) at minimum the ability to detect Plasmodium genus and P. falciparum, 3) temperature 
stability, 4) turnaround time of less than 2 days [2] and 5) an analytical sensitivity of 2 
parasites/ µL [3]. While it has been suggested that assays with the capacity for high 
throughput may be required for the purposes of malaria elimination [4], the definition of ‘high-
throughput’ remains unclear, and is likely to be determined by the type of approach taken to 
achieve and maintain malaria elimination. 
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In this thesis, I aimed to develop a molecular diagnostic tool based on loop mediated 
isothermal amplification (LAMP) technology that could be used for the purpose of malaria 
elimination. 
As outlined in Chapter Two, while there are many sensitive, novel, molecular diagnostic 
platforms currently available which utilise PCR, LAMP and serology, these modalities lack the 
ability to be performed in resource-limited settings and have low throughput. LAMP is 
currently at the forefront of molecular diagnostic technology, and appears to have potential for 
addressing these two limitations by virtue of its isothermal nature and ability to amplify crudely 
extracted DNA while maintaining sensitivity and specificity. Nevertheless, LAMP platforms 
currently available continue to be limited in their capacity for increasing throughput as might 
be required for the purpose of malaria elimination. 
 As such, this thesis aimed to address two questions- can LAMP be optimised to a simple, 
cost effective format able to process a large number of samples simultaneously? Can LAMP 
in this format be performed in a resource limited setting while maintaining sensitivity and 
specificity? 
Chapter Three outlined the optimisation of LAMP into a high throughput platform, using the 
work of Goto et al [5] as a starting point, and exploring cost effective techniques for DNA 
extraction that also facilitated a fast turnaround time for the assay. It would appear that for 
HtLAMP, as for PCR, there is a compromise between turnaround time and maintaining 
sensitivity, particularly for processing filter paper samples using relatively crude DNA 
extraction protocols such as the chelex and saponin protocol. This may have important 
implications for the logistics of malaria elimination programs in choosing not only the most 
sensitive platform but the type of sample collected and the method of DNA extraction along 
with its associated costs. 
Nevertheless, the HtLAMP platform is able to process 85 samples (allowing for 9 negative 
controls and 2 positive controls) in a standard 96 well microtitre plate format, with a 
turnaround time of 4 hours for whole blood samples, and 6 hours for filter paper samples at 
an estimated cost of USD 1 per sample including DNA extraction and primers. 
134 
 
The HtLAMP platform was validated in a resource limited laboratory setting in Kota Marudu, 
Sabah, Malaysia. The assay was performed in a plastic bucket that was transformed into a 
waterbath, with DNA extracted from filter paper on-site using the chelex-saponin protocols. 
Spatial separation of work spaces was used to avoid contamination. Local laboratory staff 
were trained in the processes of both DNA extraction and the HtLAMP assay performance 
and interpretation over a 3 day period. In this setting, HtLAMP performed with good diagnostic 
accuracy for the detection of Plasmodium falciparum in patients symptomatic with patent 
parasitemia, demonstrating a sensitivity of 100% (n=17/17, 95% CI 80-100) and specificity of 
95% (n=123/128, 95% CI 90-98) compared with multiplex PCR thereby giving confidence in 
the potential for the HtLAMP assay to be a field applicable molecular diagnostic tool with the 
capacity for high throughput.  
The HtLAMP platform was validated using previously published primers [6] for detecting P. 
falciparum and Plasmodium genus. However, LAMP-based modalities currently available for 
specific identification of P. vivax are limited to 3 platforms [7-9] with limits of detection of 
between 125- 500 parasites/ µL [8], a level that is insufficiently sensitive for the purpose of 
malaria elimination. Therefore, given its wide geographical distribution [10] and increasing 
appreciation of the extent of its asymptomatic submicroscopic reservoir [11], I investigated the 
potential for using the HtLAMP platform for the diagnosis of P. vivax. 
Based on the work of Polley et al. that demonstrated superior sensitivity of LAMP using 
primers to mitochondrial targets, achieving limits of detection of 5 parasites/ µL [6], as outlined 
in Chapter Four, I developed and validated novel P. vivax LAMP primers targeting the 
mitochondrial cox1 gene. Although these primers cross reacted with P. knowlesi given their 
97% sequence homology at the target gene site, the HtLAMP-Pv assay demonstrated good 
sensitivity and specificity when performed in a resource limited laboratory setting using filter 
paper samples from symptomatic patients and red cell pellets from asymptomatic patients. 
Furthermore, the issue of cross reactivity is likely to be of clinical importance only in a very 
limited region of south-east Asia where the distribution of P. knowlesi may overlap with that of 
P. vivax [12].  
 In an effort to further improve the availability of Plasmodium species-specific HtLAMP assays 
and address the lack of reliable and sensitive diagnostic tools in resource limited settings for 
135 
 
the identification of P. knowlesi, I then aimed to optimise HtLAMP for the detection of P. 
knowlesi by developing novel, highly sensitive P. knowlesi LAMP primers. As described in 
Chapter Five, the HtLAMP-Pk assay had a limit of detection of 0.2 parasites /µL, and 
sensitivity that was better than previously published P. knowlesi LAMP primers [13, 14]. While 
the issue of cross reactivity with P. vivax remained, this was seen to lesser extent than that 
with the HtLAMP-Pv assay. Given the high sequence homology between these two species at 
this target site, it is unlikely that further modification of these primers will be able to ameliorate 
this cross reactivity and other mitochondrial targets may need to be explored to achieve 
equivalent sensitivity without the cross-reactivity. Additionally, due to constraints of time and 
availability of samples, the HtLAMP-Pk assay underwent only a limited validation on clinical 
samples. Therefore, the assay requires validation in a more extensive set of clinical samples 
from both symptomatic and asymptomatic patients with P. knowlesi, ideally performed in a 
resource limited laboratory setting. 
There are some limitations to the work presented in this thesis. Firstly, for the HtLAMP 
platform, commercial DNA extraction kits were not evaluated due to the objective of 
maintaining low costs. However, this aspect may have helped established a baseline best 
case scenario for the HtLAMP platform in terms of its best achievable sensitivity and 
specificity albeit at higher cost. Additionally, other non-commercial DNA extraction modalities 
may be available to improve the turnaround time of the HtLAMP assay. These were not 
evaluated exhaustively in this thesis due to time constraints. Secondly, while HtLAMP has 
been validated in terms of its ability to be performed in a resource limited setting, it still relies 
on an electricity source and freezer for storage of reagents. Commercially available Loopamp 
kits (Eiken Chemical co. Ltd, Japan) have all LAMP reagents lyophilised within a tube, 
thereby setting a precedent for ways to overcome the issue of reagent storage. However, the 
technical challenge of lyophilisation of reagents for HtLAMP was not evaluated in this study. 
This aspect would have significantly improved the field applicability of the assay. Finally, while 
HtLAMP appears to perform well in symptomatic patients with patent parasitemia, the 
HtLAMP platform has had only limited validation on clinical samples from asymptomatic 
patients with submicroscopic parasitemia. This is a very important component of confirming 
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the potential role for HtLAMP, particularly for the purpose of malaria elimination, and a larger 
sample set, of either whole blood or filter paper, is required to complete this validation. 
 
Conclusions 
In this thesis I have outlined the development and validation of a simple, colourimetric, cost 
effective platform for increasing the throughput of LAMP, which can be performed on DNA 
extracted from both whole blood and filter paper. I have also demonstrated that this HtLAMP 
assay can be successfully performed in a resource limited laboratory setting using minimal 
equipment of a centrifuge, water bath and portable spectrophotometer. I also developed and 
validated two novel sets of sensitive LAMP primers for the detection of P. vivax and P. 
knowlesi which can be used in the HtLAMP platform, thereby improving the capacity for high 
throughput detection of these organisms in a resource limited laboratory setting. 
Future work might consolidate aspects of the assay that could facilitate easier deployment in 
resource limited setting such as lyophilisation to improve temperature stability and alternative 
DNA extraction modalities to improve the turnaround time of the assay. In addition, given the 
cross reactivity of these LAMP primers between P. vivax and P. knowlesi, efforts must be 
invested on improving the species specificity of HtLAMP. Furthermore, based on this work, 
which has confirmed the superior analytical sensitivity achieved with developing LAMP 
primers targeting mitochondrial genes, further work may also lead to optimisation of HtLAMP 
for specific detection of the other clinically relevant Plasmodium species. Finally, further 
validation of the HtLAMP assay, in a large sample set consisting of both symptomatic and 
asymptomatic patients with low level parasitemia from a variety of geographical locations with 
differing prevalence of Plasmodium species, would strengthen the confidence in the accuracy 
and reliability of the assay. 
As more countries approach malaria elimination, the demand for cost effective, field 
deployable sensitive molecular diagnostic tools will increase. The HtLAMP platform offers the 
potential to meet the diagnostic needs of the malaria elimination agenda and contribute to the 
process of achieving the ambitions of malaria elimination. 
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